Systems and methods for processing clinical trial data

By combining ruxolitinib and natedeline in combination therapy, patient response was assessed, addressing the issue of suboptimal response to ruxolitinib therapy. This significantly improved spleen volume reduction and overall symptom score in patients with myeloproliferative neoplasms, and prolonged patient survival.

CN123125657APending Publication Date: 2026-11-17KARTOS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580028377.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-12-02
Filing Date
2025-02-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current Janus kinase inhibitors for treating myeloproliferative neoplasms, such as ruxotinib, have only a suboptimal response in some patients and do not significantly improve disease pathology or patient survival, indicating a need for improved treatment methods.

Method used

Combination therapy, including the combined use of ruxotinib and natedeline, was used to determine whether the combination therapy improved myeloproliferative neoplasm-related endpoints, such as spleen volume reduction and total symptom score reduction, relative to ruxotinib monotherapy, by evaluating patients' clinical data and responses.

Benefits of technology

It significantly improved spleen volume reduction and overall symptom score reduction in patients with a suboptimal response to ruxotinib, prolonged patient survival, and reduced the frequency of driver gene variant alleles.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123125657A_ABST
    Figure CN123125657A_ABST
Patent Text Reader

Abstract

A system and method are provided for determining whether combination therapy improves an endpoint associated with myeloproliferative neoplasms (MPN) relative to monotherapy. Data from subjects with MPN are obtained, including a first baseline measurement before treatment and a first response after a first treatment with the first composition. A subset of subjects meeting a response threshold is identified and divided into a first arm and a second arm for a second treatment, the first arm receiving the first composition and the second composition, and the second arm receiving the first composition and a placebo. A second response is received after the second treatment. The subjects in the subset are evaluated by comparing the second response to the first baseline measurement or an optional second baseline measurement obtained after the first and second arm division and before the second treatment, thereby determining whether the combination therapy in the first arm improves the MPN-related endpoint relative to monotherapy with the first composition.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates in general to systems and methods for using clinical trial data to determine treatments that improve clinically relevant endpoints, particularly those related to myeloproliferative neoplasms. Background Technology

[0002] Myelofibrosis (including primary MF, post-PVMF, or post-ETMF) is a clonal myeloproliferative neoplasm (MPN) characterized by progressive myelofibrosis and subsequent ineffective erythropoiesis, dysplastic megakaryocyte proliferation, and extramedullary hematopoiesis. Typical clinical presentations include significant splenomegaly, progressive anemia, and systemic symptoms. Other risk factors for poor prognosis include age over 65 years, hemoglobin levels below 10 g / dL, and a white blood cell count (WBC) greater than 25 x 10^6. 9 The number of cells / L and the percentage of blast cells in the blood are higher than or equal to 1%. The median survival at diagnosis for patients with high-risk disease is approximately 2 years (Cervantes 2009).

[0003] MF is a clonal stem cell disease characterized by molecular alterations in driver genes (e.g., JAK2, MPL, CALR) and cytogenetic markers (e.g., 13q-, 20q-) (Pikman 2006; Hussein 2009). The JAK2 V617F mutation, leading to overactivation of signaling from cytokine and growth factor receptors in hematopoietic progenitor cells, has been identified in over 95% of PV patients and approximately 50% of ET and PMF patients.

[0004] Ruxotinib is a Janus kinase inhibitor approved in the US and EU for the treatment of intermediate- or high-risk myocardial infarction (MF), including post-periodic MF (PMF), post-periodic MF (PV), and post-exocrine MF (ET) (Jakafi Prescribing Information). Treatment with ruxotinib results in a significant reduction in spleen volume (e.g., SVR ≥ 35%) in approximately 28% to 42% of MF patients and provides significant improvement in systemic symptoms (e.g., a reduction in total symptom score (TSS) ≥ 50%) in approximately 46% of MF patients (Harrison 2012; Verstovsek 2012). However, only about a quarter (e.g., 20–25%) of responding patients achieve both an SVR ≥ 35% and a TSS ≥ 50%. On the other hand, a small percentage of patients do not achieve any clinically meaningful response after treatment with ruxotinib (e.g., in the primary refractory population). The reported benefits of reduced SVR and TSS from ruxotinib treatment were achieved within 12 weeks of treatment initiation, after which maintenance of ruxotinib administration did not deepen the therapeutic response (Verstovsek 2012). Ruxotinib did not significantly affect the variant allele frequency (VAF) of myelofibrosis or driver mutations (e.g., JAK2 or CALR) during the first 1–2 years of treatment, suggesting no effect on the underlying disease pathology (Verstovesek 2012). Finally, approximately 50% of MF patients discontinued ruxotinib treatment within 3 years (Harrison 2016; Al-Ali 2017; Verstovsek 2017), with failure to achieve significant SVR or loss of SVR accounting for approximately 35% of all discontinuation patients (Palandri 2020). Summary of the Invention

[0005] Given the above background, there is an unmet need for improved therapies for patients with clinical conditions exhibiting a suboptimal response to conventional treatments. What is needed in the art are systems and methods for improved therapies for patients with myeloproliferative neoplasms (MPNs) who have a suboptimal response to first-line monotherapy, including Janus kinase (JAK) inhibitor (JAKi) monotherapy, such as ruxotinib monotherapy as standard treatment.

[0006] This disclosure addresses the need in the art for systems and methods for improving treatment by providing systems and methods that include combination therapies (e.g., concurrent, sequential, and / or additional) to improve one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy, said combination therapies comprising a combination of a first composition and a second composition. Advantageously, in some embodiments, the systems and methods of this disclosure identify a subset of subjects with a suboptimal response to monotherapy (e.g., JAKi monotherapy) and utilize this subset to evaluate and determine whether the combination of the first composition and the second composition improves one or more endpoints relative to monotherapy, for example, to address the aforementioned need in the art. As shown in Examples 2-8 below, preclinical study results have indicated that, in some implementations, navtemadlin and ruxolitinib, when used in combination, synergistically increase TP53 WT Apoptotic cell death in JAK2 V617F MPN cell line (UKE-1) and CD34+ myeloid progenitor cells collected from blood of patients with chronic MF.

[0007] One aspect of this disclosure provides a method for determining whether combination therapy with a first composition and a second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition (e.g., JAKi monotherapy, such as ruxotinib monotherapy). In some embodiments, the first composition is ruxotinib. In some embodiments, the method includes obtaining clinical data involving multiple subjects suffering from myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition for myeloproliferative neoplasms and (ii) a corresponding first set of responses following a first treatment period with the first composition.

[0008] In some embodiments, the method further includes identifying subsets of subjects from a plurality of subjects, each meeting a suboptimal response threshold. In some embodiments, the subject subsets are randomly divided into a first arm and a second arm, wherein for a second treatment period, subjects in the first arm receive a combination of the first composition and the second composition, while subjects in the second arm receive a combination of the first composition and a placebo. In some embodiments, the second composition is naledrin.

[0009] In some embodiments, for each corresponding subject in the subset of subjects, the method further includes obtaining a corresponding second response set upon completion of the second treatment period. In some embodiments, each corresponding subject in the subset of subjects is evaluated by comparing the corresponding second response set with (a) a corresponding first set of baseline measurements for the corresponding subject and / or (b) optional corresponding second set of baseline measurements obtained for the corresponding subject after the subset of subjects is divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, thereby determining whether the combination of the first treatment and the second treatment in the first arm improves one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition.

[0010] In some implementations, each corresponding subject in a subset of subjects is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding first set of baseline measurements.

[0011] In some implementations, the method further includes obtaining corresponding second-group baseline measurements for the respective subjects after the subject subset is divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and a placebo, and assessing each respective subject in the subject subset by comparing the corresponding second-group baseline measurements with the corresponding second-group baseline measurements.

[0012] Another aspect of this disclosure includes a method for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, the method comprising: Obtain clinical data involving multiple subjects with myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition and (ii) a corresponding first set of responses after a first treatment period with the first composition; Identify subsets of subjects from multiple subjects, each of whom meets the suboptimal response threshold; For the second treatment period, the combination of the first and second compositions is administered to a subset of subjects who each meet the suboptimal response threshold from among multiple subjects. For each corresponding subject in the subset of subjects, a corresponding second response set is obtained upon completion of the second treatment period; and Each corresponding subject in the subject subset is evaluated by comparing the corresponding second response set with the following: (a) The corresponding baseline measurements of the first group for the relevant subjects, and / or (b) Optional second set of baseline measurements obtained from the respective subjects prior to the second treatment period. This determines whether the combination of the first and second treatments improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition.

[0013] Another aspect of this disclosure includes a system for determining whether combined treatment with a first composition and a second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, comprising a display, an input device, one or more processors, and a memory storing one or more programs, which, when executed by the one or more processors, cause the processors to perform any of the methods disclosed above.

[0014] Another aspect of this disclosure includes a non-transitory computer-readable storage medium having stored program code instructions for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, the instructions, when executed by a processor, causing the processor to perform any of the methods disclosed above. Attached Figure Description

[0015] Figure 1A , 1B 1C illustrates an exemplary system topology according to some embodiments of the present disclosure for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition.

[0016] Figure 2A , 2B Together with 2C, a flowchart is provided of a process and characteristics for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, according to some embodiments of this disclosure, wherein optional steps are indicated by dashed lines.

[0017] Figure 3An exemplary diagram of a randomized, double-blind study according to one embodiment of this disclosure is shown, evaluating the safety and efficacy of natedrine plus ruxtinib versus placebo plus ruxtinib in patients with myelofibrosis who have a suboptimal response to ruxtinib. Each treatment cycle is 28 days. 1: Stable ruxtinib dose is defined as a dose of ≥5 mg BID that is administered without interruption or dose adjustment during the 8 weeks prior to natedrine adjunctive therapy. 2: Ruxtinib will be administered continuously at a stable ruxtinib dose. 3: Baseline assessment during the lead-up period is performed before the initiation of ruxtinib monotherapy. 4: After ≥18 weeks but <25 weeks of treatment, the response to ruxtinib monotherapy will be assessed in subjects who have received a stable dose of ruxtinib for ≥6 consecutive weeks (e.g., a dose of ≥5 mg BID that is administered without interruption or dose adjustment). Randomization baseline is set at a stable ruxtinib dose for ≥8 consecutive weeks. In some implementations, response assessment during the lead-up period is permitted after ≥6 weeks of stable dose. Abbreviations: JAK, Janus kinase; MF, myelofibrosis; QD, daily; SVR, spleen volume reduction; TSS, total symptom score; EOS, end of study.

[0018] Figure 4 Exemplary graphs are shown to illustrate that, according to one embodiment of this disclosure, the combination of natedeline and ruxolitinib enhances apoptosis in progenitor cells derived from MF patients. Abbreviations: MFI, median fluorescence intensity; NVTM, natedeline; Rux, ruxolitinib. Live cells are defined as CD45+mid, SSClow, CD14-, cPARP.

[0019] Figure 5 An exemplary graph is shown to illustrate that, according to one embodiment of this disclosure, the combination of nutedrin and ruxolitinib reduces the level of pro-survival MCL-1. Abbreviations: MFI, median fluorescence intensity; NVTM, nutedrin; Rux, ruxolitinib.

[0020] Figure 6A , 6B Together with 6C, it is shown that, according to one embodiment of this disclosure, the cytotoxicity of natedeline as a monotherapy or as an adjunct to ruxolitinib is associated with a reduction in spleen volume. Figure 6A Nattedrin-induced CD34 + Decreased cell count is associated with SVR; Figure 6B and 6C CD34 + Changes in cell count. Abbreviations: C1D1, Day 1 of Cycle 1; SVR-35, spleen volume reduction ≥35%. Figure 6C Data from one patient with a cell concentration of 0 cells / μL at week 24 were not presented.

[0021] Figure 7 Exemplary graphs are provided to illustrate, according to one embodiment of this disclosure, that the reduced allele frequency of naturedrin-induced driver gene variants is associated with PFS and OS.

[0022] Figure 8 Exemplary diagrams are provided to illustrate, according to one embodiment of this disclosure, naturedrin-induced CD34 + Decreased cell count is associated with progression-free survival (PFS) and overall survival (OS).

[0023] Figure 9 This illustration shows a reduction in spleen volume following the addition of a stable dose of ruxolitinib to atatedrine, according to one embodiment of this disclosure. Evaluable subjects with spleen volume assessments at baseline and week 24 are shown. Six subjects discontinued treatment before week 24.

[0024] Figure 10 An embodiment of the present disclosure shows a reduction in total symptom scores after adding natedrine to a stable dose of ruxolitinib.

[0025] Figure 11 It is shown that, according to one embodiment of this disclosure, the addition of atedrin to ruxolitinib resulted in a decrease in the frequency of driver gene variant alleles and an improvement in myelofibrosis. Abbreviations: BM, bone marrow; CALR, calreticulin; JAK2, Janus kinase; MF, myelofibrosis; VAF, variant allele frequency.

[0026] Figure 12 A proposed multi-component spleen response endpoint based on spleen volume reduction is provided according to one embodiment of this disclosure. Figure 12 In this study, patients achieving a spleen volume reduction of 35 from their pre-ruxolitinib baseline were defined as responders (even if they achieved a spleen volume reduction of 25 from their pre-randomization baseline), thus attributing a clinically meaningful benefit to the patient based on established thresholds. Abbreviations: SVR, spleen volume reduction; SVR35, spleen volume reduction ≥35%; SVR25, spleen volume reduction ≥25%.

[0027] Figure 13 A proposed multi-component spleen response endpoint based on TSS is provided according to one embodiment of this disclosure. Figure 13 In this study, patients who achieved a TSS50 from their pre-ruxolitinib baseline were defined as responders (even if they achieved a TSS30 from their pre-randomization baseline), thus attributing a clinically meaningful benefit to the patient based on predetermined thresholds. Abbreviations: TSS, Total Symptom Score; TSS30, TSS reduction ≥30%; TSS50, TSS reduction ≥50%.

[0028] Figure 14This illustration shows spleen and symptom suboptimal responders from pooled phase 3 ruxolitinib data according to one embodiment of this disclosure. Pooled extractable data were obtained from patients who received ruxolitinib monotherapy (± placebo) in the published phase 3 JAKi-naïve MF studies. SVR (N=465): COMFORT-1, SIMPLIFFY-1, and TRANSFORM-1 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). TSS (N=528): COMFORT-1, SIMPLIFFY-1, and MANIFEST-2 (Verstovsek 2012; Mesa 2017; Rampal 2023). Week 24 data were used as a surrogate measure for assessing suboptimal response at week 18. Abbreviations: SVR, spleen volume reduction; TSS, total symptom score.

[0029] Figure 15 The following illustrates a suboptimal spleen response based on the SVR25 threshold according to one embodiment of this disclosure. Using pooled datasets, a mean SVR of 18% was identified among JAKi-naïve MF patients with a suboptimal response to ruxotinib. Pooled studies: suboptimal spleen response to ruxotinib monotherapy (± placebo) was >0 but ≤35% (N=253; COMFORT-I, SIMPLIFFY-1, TRANSFORM-1). Week 24 data were used as a surrogate for the week 18 suboptimal response assessment. SVR: spleen volume reduction; SVR25: spleen volume reduction ≥25%.

[0030] Figure 16 The following illustrates a suboptimal TSS responder based on the TSS30 response threshold according to one embodiment of this disclosure. Using a pooled dataset, a mean TSS reduction of 28.5% was identified in JAKi-naïve MF patients with a suboptimal response to ruxolitinib. Pooled studies: Suboptimal symptom response to ruxolitinib monotherapy (± placebo) was >0% but <50%. TSS, total symptom score; TSS30, TSS reduction ≥30%.

[0031] Figure 17The KRT-232-109 study, according to one embodiment of this disclosure, demonstrates spleen volume reduction following the addition of atedrin to a stable dose of ruxotinib. The KRT-232-109 study was a phase 2 study of the addition of atedrin in patients with a suboptimal response to ruxotinib. Note: Evaluable subjects with spleen volume assessments at baseline and week 24 are shown. Baseline spleen volume MRI / CT scans were performed while subjects received a stable dose of ruxotinib for ≥8 weeks (e.g., no ruxotinib washout). No ruxotinib dose escalation above the stable baseline dose occurred during the 24-week evaluation period. The median duration of ruxotinib treatment prior to the addition of atedrin was 21.6 months (range: 7 to 129). Six participants discontinued treatment before week 24. Abbreviations: ITT, intention-to-treat; Rux, ruxolitinib; yrs, years.

[0032] Figure 18 A clinical trial (e.g., the KRT-232-109 study) according to one embodiment of this disclosure is shown, demonstrating a reduction in total symptom scores following the addition of atedrin to a stable dose of ruxotinib. The KRT-232-109 study was a phase 2 study of the addition of atedrin in patients with a suboptimal response to ruxotinib. Note: Baseline TSS assessment was performed while subjects were receiving a stable dose of ruxotinib for ≥8 weeks (e.g., no ruxotinib washout). No ruxotinib dose escalation above the stable baseline dose occurred during the 24-week assessment period. The median duration of ruxotinib treatment prior to the addition of atedrin was 21.6 months (range: 7 to 129). Six subjects discontinued treatment before week 24. Abbreviations: MFSAF, Symptom Assessment Scale for Myelofibrosis; ITT, Intention to Treatment; Rux, Ruxotinib; TSS, Total Symptom Score; yrs, Years.

[0033] Figure 19This illustration shows the expected SVR of adding natedrine to ruxolitinib according to one embodiment of this disclosure. Spleen volume reduction is modeled by KRT-232-109 and published phase 3 myelofibrosis studies. Note: Light gray bars depict the baseline SVR distribution, based on pooled extractable data from published phase 3 JAKi-naïve MF studies in patients with suboptimal splenic responses to ruxolitinib monotherapy (± placebo); COMFORT-1, SIMPLIFY-1, and TRANSFORM-1 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). Blue bars (regardless of shade) show the expected additional benefit in patients treated with added natedrine. The darkest blue bars depict SVR25 responders from pre-randomization baseline, which also cross the SVR35 threshold from pre-ruxolitinib baseline (e.g., the proposed multi-component SVR endpoint). Abbreviations: CT, Computed Tomography; LOCF, Last Observation Carryover; MF, Myelofibrosis; MRI, Magnetic Resonance Imaging; Rux, Ruxotinib; SVR, Spleen Volume Response; SVR25, Spleen volume reduction ≥25%; SVR35, Spleen volume reduction ≥35%.

[0034] Figure 20 This diagram illustrates the anticipated SVR with placebo added to ruxolitinib according to one embodiment of this disclosure. Splenic volume reduction is modeled by KRT-232-109 and published phase 3 myelofibrosis studies. Note: Light gray bars depict the baseline SVR distribution based on pooled extractable data from published phase 3 JAKi-naïve MF studies in patients with suboptimal splenic responses to ruxolitinib monotherapy (± placebo); COMFORT-1, SIMPLIFY-1, and TRANSFORM-1 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). Dark gray bars show the anticipated additional benefit in patients treated with placebo. No patients (0%) were modeled as achieving the proposed multi-component SVR endpoints of SVR25 from pre-randomization baseline and SVR35 from pre-ruxolitinib baseline. Abbreviations: CT, Computed Tomography; LOCF, Last Observation Carryover; MF, Myelofibrosis; MRI, Magnetic Resonance Imaging; Rux, Ruxotinib; SVR, Spleen Volume Response; SVR25, Spleen volume reduction ≥25%; SVR35, Spleen volume reduction ≥35%.

[0035] Figure 21This diagram illustrates the expected TSS (Total Symptom Score) of adding natedrine to ruxolitinib according to one embodiment of this disclosure. Total symptom scores are modeled by KRT-232-109 and published phase 3 myelofibrosis studies. Note: Light gray bars depict the baseline distribution of TSS reduction, based on pooled extractable data from published phase 3 JAKi-naïve MF studies in patients with suboptimal symptom responses to ruxolitinib monotherapy (± placebo); COMFORT-1, SIMPLIFY-1, and MANIFEST-2 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). Green bars (regardless of shade) show the expected additional symptom benefit in patients treated with additional natedrine. The darkest green bars depict TSS30 responders from pre-randomization baseline, which also cross the TSS50 threshold (the proposed multi-component TSS endpoint) from pre-ruxolitinib baseline. Abbreviations: CT, Computed Tomography; LOCF, Last Observation Carryover; MF, Myelofibrosis; MRI, Magnetic Resonance Imaging; Rux, Ruxotinib; TSS, Total Symptom Score; TSS30, Total Symptom Score Reduction ≥30%; TSS50, Total Symptom Score Reduction ≥50%.

[0036] Figure 22 This diagram illustrates the expected TSS reduction with the addition of placebo to ruxotinib according to one embodiment of this disclosure. Total symptom scores are modeled by KRT-232-109 and published phase 3 myelofibrosis studies. Note: Light gray bars depict the baseline distribution of TSS reduction based on pooled extractable data from published phase 3 JAKi-naïve MF studies in patients with suboptimal symptom responses to ruxotinib monotherapy (± placebo); COMFORT-1, SIMPLIFY-1, and MANIFEST-2 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). Dark gray bars show the expected additional benefit in patients treated with additional placebo. Black bars depict TSS30 responders from pre-randomization baseline, which also cross the TSS50 threshold from pre-ruxotinib baseline (e.g., the proposed multi-component TSS endpoint). Abbreviations: CT, Computed Tomography; LOCF, Last Observation Carryover; MF, Myelofibrosis; MRI, Magnetic Resonance Imaging; Rux, Ruxotinib; TSS, Total Symptom Score; TSS30, Total Symptom Score Reduction ≥30%; TSS50, Total Symptom Score Reduction ≥50%.

[0037] Throughout the various views in the accompanying drawings, the same reference numerals refer to the corresponding parts. Detailed Implementation

[0038] Given the above background, there is an unmet need for improved therapies for patients with clinical conditions who have a suboptimal response to conventional treatments. What is needed in the art are systems and methods for improved therapies for patients with myeloproliferative neoplasms (MPNs) who have a suboptimal response to standard first-line Janus kinase (JAK) inhibitors such as ruxotinib monotherapy.

[0039] Advantageously, the subject matter of this disclosure addresses the identified needs in the art by providing systems and methods for determining whether combination therapy with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition. In some embodiments, the method includes obtaining clinical data from a subject suffering from MPN, wherein the clinical data includes a first baseline measurement prior to treatment and a first response following a first treatment with the first composition (e.g., ruxotinib). In some embodiments, the first baseline measurement includes a first baseline spleen volume measurement. In some embodiments, the first baseline measurement includes a first baseline total symptom score (TSS) measurement. In some embodiments, the first baseline measurement includes a first baseline total symptom score (TSS) measurement, wherein the total symptom score is determined using the Myelofibrosis Symptom Assessment Scale (MFSAF). In some implementations, the first baseline measurement includes a first baseline quality of life measurement, wherein quality of life is determined using the Universal Quality of Life Questionnaire (EQ-5D), eHEALS, the EORTC QLG Core Questionnaire (EORTC QLQ-C30), the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and / or the Patient Activation Scale (PAM-13). A subset of subjects meeting the response threshold is identified and divided into a first arm and a second arm for second treatment, with the first arm receiving the first composition and the second composition (e.g., natadeline), and the second arm receiving the first composition and a placebo. A second response is received after the second treatment. Subjects in the subset are assessed by comparing the second response to the first baseline measurement or an optional second baseline measurement obtained after the first and second arm division and before the second treatment to determine whether the combination therapy in the first arm improved the MPN-related endpoint relative to monotherapy with the first composition. In some implementations, the second baseline measurement includes a second baseline spleen volume measurement. In some implementations, the second baseline measurement includes a second baseline Total Symptom Score (TSS) measurement. In some implementations, the second baseline measurement includes a second baseline total symptom score (TSS) measurement, wherein the total symptom score is determined using the Myelofibrosis Symptom Assessment Scale (MFSAF). In some implementations, the second baseline measurement includes a second baseline quality of life measurement, wherein the quality of life is determined using the General Quality of Life Questionnaire (EQ-5D), eHEALS, the EORTC QLQ-C30 Core Questionnaire, the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and / or the Patient Activation Scale (PAM-13).

[0040] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings. Numerous specific details are set forth in the following detailed description to provide a thorough understanding of this disclosure. However, it will be apparent to those skilled in the art that this disclosure can be practiced without these specific details. In other instances, well-known methods, procedures, components, circuits, and networks have not been described in detail to avoid unnecessarily obscuring aspects of the embodiments.

[0041] definition Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains. As used herein, unless otherwise stated, the following terms as used herein have the meanings attributed to them.

[0042] As used herein, the terms “about” or “approximately” mean, as determined by one of ordinary skill in the art, an acceptable range of error for a particular value, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to practice in the art, “about” may mean within or greater than 3 standard deviations. Alternatively, “about” may mean a range of up to 20% of a given value, such as up to 10%, up to 5%, or up to 1%. Alternatively, particularly for biological systems or methods, the term may mean within an order of magnitude, such as within 5 times or 2 times the value.

[0043] As used herein, the term "subject" refers to any animal (e.g., a mammal), including but not limited to humans and non-human animals (including but not limited to non-human primates, dogs, cats, rodents, horses, cattle, pigs, mice, rats, hamsters, rabbits, etc., for example, which will be the recipient of a particular treatment or from which cells will be harvested). In some embodiments, the subject is a human.

[0044] As used herein, the term "treatment" refers to a clinical intervention aimed at altering the course of a disease in the treated individual or cells, and may be for prevention or in the course of clinicopathological processes. The therapeutic effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. By preventing the progression of the disease or condition, treatment can prevent exacerbations caused by the condition in affected or diagnosed or suspected subjects, and treatment can also prevent the onset of the condition or its symptoms in subjects at risk or suspected of having the condition.

[0045] As used herein, an "effective dose" or "therapeutic effective dose" refers to a dose sufficient to produce a beneficial or desired clinical outcome during treatment. An effective dose may be administered to a subject at one or more doses. In therapeutic terms, an effective dose is a dose sufficient to reduce, improve, stabilize, reverse, or slow disease progression, or otherwise reduce the pathological consequences of the disease. An effective dose is typically determined by a physician on a case-by-case basis and within the competence of a person skilled in the art. Several factors are typically considered when determining the appropriate dose to achieve an effective dose. These factors include the subject's age, sex, and weight; the condition being treated; the severity of the condition; and the form and effective concentration of the immunoreactive cells administered.

[0046] As used herein, the terms “diagnosis” or “diagnosed” refer to determining whether a subject is likely to be affected by a given disease, condition, or dysfunction. Those skilled in the art will understand that a diagnosis can be based on one or more diagnostic indicators, including but not limited to, biomarkers, imaging, and / or symptoms, the presence, absence, or quantity of which indicates the presence or absence of a disease, condition, or dysfunction.

[0047] It will also be understood that although the terms first, second, etc., may be used herein to describe various elements, these elements should not be limited by these terms. These terms are used only to distinguish one element from another. For example, a first subject may be referred to as a second subject, and similarly, a second subject may be referred to as a first subject, without departing from the scope of this disclosure. Both a first subject and a second subject are subjects, but they are not the same subject. Furthermore, the terms "subject," "user," and "patient" are used interchangeably herein.

[0048] The terminology used in this disclosure is for the purpose of describing particular embodiments only and is not intended to limit the invention. As used in the description of the invention and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will also be understood that the term “and / or” as used herein refers to and covers any and all possible combinations of one or more of the associated listed items. It will be further understood that, when used in this specification, the terms “comprises” and / or “comprising” specify the presence of the stated features, integers, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0049] As used herein, depending on the context, the term "if" can be interpreted as meaning "when," "at," "in response to determination," or "in response to detection." Similarly, depending on the context, the phrase "if determination" or "if [the condition or event] is detected" can be interpreted as meaning "when determination," "in response to determination," "when [the condition or event] is detected," or "in response to detection."

[0050] Exemplary System for Determining Endpoint Improvement One aspect of this disclosure provides a system for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition.

[0051] Combination Figure 1A-1C This describes in detail a system 100 according to the present disclosure for determining whether combined treatment with the first composition and the second composition improves one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition. Therefore, Figure 1A-1C The topology of a system according to this disclosure is illustrated. In this topology, there is a system 100 for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition.

[0052] refer to Figure 1A-1C In some implementations, system 100 receives data directly or indirectly via radio frequency signals. In some implementations, such signals conform to the 802.11 (WiFi), Bluetooth, or ZigBee standards. In some implementations, system 100 receives data through one or more communication networks 16.

[0053] Examples of network 16 include, but are not limited to, the World Wide Web (WWW), intranets and / or wireless networks, such as cellular telephone networks, wireless local area networks (LANs) and / or metropolitan area networks (MANs), and other devices that communicate wirelessly. Wireless communication may optionally use any of a variety of communication standards, protocols, and technologies, including but not limited to Global System for Mobile Communications (GSM), Enhanced Data GSM Environment (EDGE), High-Speed ​​Downlink Packet Access (HSDPA), High-Speed ​​Uplink Packet Access (HSUPA), Evolved Data Dedicated (EV-DO), HSPA, HSPA+, Dual-Carrier HSPA (DC-HSPDA), Long Term Evolution (LTE), Near Field Communication (NFC), Wideband Code Division Multiple Access (W-CDMA), Code Division Multiple Access (CDMA), Time Division Multiple Access (TDMA), Bluetooth, and Wi-Fi (e.g., IEEE 802.11a, IEEE 802.11ac, IEEE 802.11ax, IEEE 802.11b, IEEE 802.11g, and / or IEEE... 802.11n), Voice over Internet Protocol (VoIP), Wi-MAX, email protocols (e.g., Internet Messaging Access Protocol (IMAP) and / or Post Office Protocol (POP)), instant messaging (e.g., Extensible Messaging and Presence Protocol (XMPP), Extended Session Initiation Protocol for Instant Messaging and Presence (SIMPLE), Instant Messaging and Presence Service (IMPS)) and / or Short Message Service (SMS), or any other suitable communication protocol, including communication protocols that have not been developed at the date of this disclosure.

[0054] certainly, Figure 1A-1C Other topologies for system 100 are also possible. For example, information can be sent directly to system 100 without relying on communication network 16. Furthermore, system 100 can constitute a portable electronic device, a server computer, or actually constitute several computers linked together in a network, or a virtual machine in a cloud computing environment. Therefore, Figure 1A-1C The exemplary topology shown is only used to describe the features of the embodiments of this disclosure in a manner that is easily understood by those skilled in the art.

[0055] refer to Figure 1A-1C In a typical implementation, system 100 includes one or more computers. In order to... Figure 1A-1CFor the purposes described herein, system 100 is represented as a single computer including all functions for determining whether combined treatment with the first composition and the second composition improves one or more endpoints related to myeloproliferative neoplasms relative to single therapy with the first composition. However, this disclosure is not limited thereto. In some embodiments, functionality is distributed across any number of networked computers and / or resides on each of several networked computers, and / or is hosted on one or more virtual machines at remote locations accessible via communications network 16. Those skilled in the art will understand that any of a variety of different computer topologies are used for this application, and all such topologies are within the scope of this disclosure.

[0056] Taking the above circumstances into consideration, the direction was changed. Figure 1A-1C An exemplary system 100 for determining whether combined treatment with a first composition and a second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition includes one or more processing units (CPUs) 74, a network or other communication interface 84, a memory 192 (e.g., random access memory), one or more disk storage and / or persistent devices 90 (optionally accessed by one or more controllers 288), one or more communication buses 13 for interconnecting the aforementioned components, a user interface 78 including a display 82 and input terminals 80 (e.g., keyboard, keypad, touchscreen), and a power supply 76 for powering the aforementioned components. In some embodiments, the input terminals 80 are touch-sensitive displays, such as touch-sensitive surfaces. In some embodiments, the user interface 78 includes one or more soft keyboard implementations. Soft keyboard implementations may include standard (QWERTY) and / or non-standard symbol configurations on the displayed icons. In some embodiments, data in the memory 92 is seamlessly shared with the non-volatile memory 90 using known computing techniques such as caching. In some embodiments, the memory 92 and / or the memory 90 include large-capacity storage remotely located relative to the central processing unit 74. In other words, some data stored in memory 92 and / or memory 90 can actually be hosted on a computer outside of system 100, but system 100 can access it electronically via the Internet, intranet or other forms of network or electronic cable (e.g., shown as element 16) using network interface 84.

[0057] In some embodiments, the memory 92 of system 100 for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition includes: Optional features include an operating system 102 for handling various basic system services; A clinical data repository for obtaining clinical data involving multiple subjects 122 (e.g., 122-1, ... 122-J) with myeloproliferative neoplasms, wherein for each corresponding subject 122 among the multiple subjects, the clinical data optionally includes and is associated with: (i) a corresponding first set of baseline measurements 124 (e.g., 124-1-1, ... 124-1-K) prior to treatment with the first composition and (ii) a corresponding first set of responses 126 (e.g., 126-1-1, ... 126-1-L) after a first treatment period with the first composition; Subset constructor 130 may optionally include: The suboptimal response threshold 132 is used to identify subsets of subjects 122 (e.g., 122-1, ... 122-M, 122-N, ... 122-P) from multiple subjects who each meet the suboptimal response threshold 132; The first arm 134-1 is divided from a subset of subjects 122 (e.g., 122-1, ... 122-M), wherein for the second treatment period, subjects in the first arm receive a combination of the first composition and the second composition; The second arm 134-2 is derived from a subset of subjects 122 (e.g., 122-N, ... 122-P), wherein for the second treatment period, subjects in the second arm receive a combination of the first composition and a placebo. For each corresponding subject 122 in the subject subset, the corresponding second response set 138 (e.g., 138-1-1, ... 138-1-R, 138-N-1, ... 138-NT) upon completion of the second treatment period; and For each corresponding subject 122 in the subject subset, there may be an optional second set of baseline measurements 136 (e.g., 136-1-1, ... 136-1-Q, 136-N-1, ... 136-NS); Endpoint data repository 140, optionally including one or more endpoints 142 (e.g., 142-1, ... 142-V) associated with myeloproliferative neoplasms; and The assessment construct 150 optionally evaluates each corresponding subject 122 in the subject subset by comparing the corresponding second response set 138 with (a) the corresponding first set of baseline measurements 124 of the corresponding subject and / or (b) the optional corresponding second set of baseline measurements 136 obtained from the corresponding subject 122 after the subject subset is divided into a first arm 134-1 and a second arm 134-2 and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, thereby determining whether the combination of the first treatment and the second treatment in the first arm 134-1 improves one or more endpoints 142 associated with myeloproliferative neoplasms relative to 134-2 as monotherapy with the first composition.

[0058] In some implementations, one or more of the data elements or modules identified above in system 100 are stored in one or more of the aforementioned memory devices and correspond to an instruction set for performing the functions described above. The identified data, modules, or programs (e.g., instruction sets) do not need to be implemented as separate software programs, processes, or modules, and therefore, in various implementations, various subsets of these modules can be combined or otherwise rearranged. In some implementations, memory 92 and / or 90 optionally stores a subset of the modules and data structures identified above. Furthermore, in some implementations, memory 92 and / or 90 stores additional modules and data structures not described above. Further still, in some implementations, system 100 stores data of two or more subjects, five or more subjects, one hundred or more subjects, or one thousand or more subjects.

[0059] In some embodiments, system 100 includes a smartphone (e.g., iPhone), a laptop computer, a tablet computer, a desktop computer, or other form of electronic device (e.g., a game console). In some embodiments, system 100 is not portable. In some embodiments, system 100 is portable.

[0060] It should be understood that Figure 1A-1C The system 100 shown is merely an example of a device that can be used to determine whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, and the system 100 may optionally have more or fewer components than shown, may optionally combine two or more components, or may optionally have different component configurations or arrangements. Figure 1A-1C The various components shown are implemented in hardware, software, firmware, or a combination thereof, including one or more signal processing and / or application-specific integrated circuits.

[0061] In some implementations, system 100 has the capability to... Figure 1A-1CAny or all circuits, hardware components, and software components found in the depicted system 100. For the sake of brevity and clarity, only a few possible components of system 100 are shown in order to better emphasize additional software modules installed on system 100.

[0062] Although Figure 1A-1C The disclosed system 100 can work independently, but in some implementations it can also be linked to electronic medical records to exchange information in any way.

[0063] Exemplary implementation scheme for determining endpoint improvement Since details of a system 100 for determining whether combination therapy with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition have been disclosed, refer to Figure 2A-2C Flowchart details of processes and features according to embodiments of this disclosure are disclosed, which may optionally be used with system 100. In some embodiments, these processes and features are provided by... Figure 1A-1C The system 100 shown is executed. In some implementations, refer to... Figure 2A-2C The process and features without using Figure 1A-1C Execute under the system conditions shown.

[0064] Figure 2A-2C Together, a method 200 is shown for determining whether combined treatment with the first composition and the second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition.

[0065] Patients with a suboptimal response to ruxolitinib As mentioned above, there is an unmet need among subjects who have a suboptimal response to ruxotinib. While ruxotinib treatment achieves significant SVR (e.g., >35%) and symptom control (e.g., TSS reduction >50%) in a subset of patients, many patients have a suboptimal response (e.g., SVR <35% and TSS reduction <50%) (Harrison 2012; Verstovsek 2012; Mesa 2017). Although in some implementations, these patients may benefit somewhat from continued ruxotinib use, spleen volume remains enlarged, and symptom burden remains clinically relevant. Therefore, maximizing SVR is important for optimizing patient outcomes, as the degree of SVR is associated with endpoints such as improvement in quality of life and overall survival (OS) as assessed by TSS. Without being limited to any particular operational theory, the smaller the spleen becomes, the greater the improvement in quality of life, and the longer the lifespan of patients with MF (Mesa 2013; Vannuchi 2015).

[0066] Traditional treatment options for improving outcomes in patients with suboptimal responses to ruxolitinib are limited. Currently, there are no approved drugs that can be added to ruxolitinib to optimize patient care. Unfortunately, as mentioned above, suboptimal responses can also lead to treatment discontinuation, and outcomes after ruxolitinib discontinuation are poor. In patients who discontinued ruxolitinib, the median overall survival (OS) was only 13.2 months (95% confidence interval [CI], 8.0–22.7 months) (Newberry 2017). In conclusion, these data clearly demonstrate an unmet medical need for improved treatment options in patients with myocardial infarction (MF) who have a suboptimal response to ruxolitinib.

[0067] Natdelin Natedeline is a potent and selective small-molecule mouse dual microsome 2 (MDM2) inhibitor that binds to human MDM2 to neutralize its interaction with p53. This restores p53-mediated activity and induces apoptosis in TP53 wild-type (WT) malignancies (Sun 2014). The primary determinant of sensitivity to MDM2 inhibition is the TP53 mutational status. Specifically, if the tumor harbors TP53 mutations that impair p53 transcriptional activity, MDM2 inhibition may fail to modulate the tumor-suppressive function of p53. Therefore, the safety and efficacy of natedeline treatment should be assessed only in relation to TP53. WT Evaluation in cancer patients. In this regard, strategies to maximize the efficacy of MDM2i may be most evident in tumor cells that have escaped normal p53 tumor suppressor function by upregulating MDM2 levels (e.g., MDM2 gene amplification, MDM2 overexpression, or MDM2 nucleoprotein upregulation).

[0068] Non-clinical pharmacology studies have shown that, in individuals representing diverse genetic backgrounds and carrying TP53, WT In xenograft models of various tumor types, natedrine drove a dose-dependent reduction in tumor growth. Natedrine treatment activated the p53 pathway, as measured by increases in cyclin-dependent kinase inhibitor (p21) mRNA (a direct transcriptional target of p53) and induction of pro-apoptotic proteins leading to tumor cell death. Preclinical studies using natedrine have yielded encouraging results in in vitro, ex vivo, and in vivo experiments representing solid tumors and hematologic malignancies, including myeloid leukemia (MF) and acute myeloid leukemia secondary to multiple myeloid neoplasms (MPN).

[0069] For naledelin, repeated-dose toxicity studies lasting up to 13 weeks have been completed in rats and monkeys, along with in vitro and in vivo safety pharmacology studies. In standard experimental groups, naledelin showed no mutagenicity or genotoxicity, and its potential phototoxicity was negligible. Because the necessity of p53 / MDM2 regulation during embryonic and fetal development is well documented, no non-clinical embryo-fetal toxicity and fertility studies of naledelin have been conducted. Based on its mechanism of action, naledelin alters cell proliferation and is expected to have adverse effects on embryonic and fetal viability and development.

[0070] Improved treatment considerations Janus kinase (JAK) inhibitors, including the JAK 1 / 2 inhibitor ruxotinib, have become the standard of care and backbone therapy for patients with massive fibrosis (MF). However, many MF patients have a suboptimal response to ruxotinib (e.g., SVR <35% and TSS reduction <50%). In this population, spleen volume remains enlarged, and symptom burden remains clinically relevant. There remains an unmet need for improved therapies with complementary mechanisms that can be safely combined with the JAKi backbone to treat MF patients with a suboptimal response to JAKi therapy. Effective new therapies will enable more patients to achieve clinically meaningful reductions in splenomegaly and symptom burden, and realize the potential for disease modification to achieve survival benefits.

[0071] MF is characterized by cyclic CD34 + Increased progenitor cells, which overexpress MDM2 due to gain-of-function mutations in upstream somatic cells (e.g., JAK2 V617F) (Nakatake 2012; Orvain 2016). MDM2 is a key negative regulator of tumor suppressor protein 53 (p53). Malignant progenitor cells overexpressing MDM2 are a key factor in the development of malignant CD34 progenitors. + Cells can escape normal p53 tumor suppression monitoring and apoptosis mechanisms.

[0072] Almost all MF patients have TP53. WT Only 2-4% of chronic-phase MF patients carry TP53 mutations (Harutyunyan 2011; Raza 2012), suggesting that MDM2 overexpression is sufficient to suppress normal p53 function in MF progenitor cells, leading to unrestricted cancer cell proliferation. Therapeutic inhibition of MDM2 offers the potential to restore normal p53 function, induce apoptosis in MDM2-overexpressing malignant MF progenitor cells, thereby complementing the immunomodulatory and antiproliferative effects of scaffold JAKi (e.g., ruxolitinib) therapy.

[0073] CD34 +The apoptosis threshold of MF progenitor cells can be influenced by factors including upstream pro-proliferative signals (e.g., constitutive JAK-STAT activation), p21-induced cell cycle arrest, and extrinsic pro-survival receptor signaling present in the supporting tumor microenvironment. Natedeline has the potential to enhance tumor cell death through synergistic effects with drugs that lower the apoptosis threshold (Vousden 2007). Preclinical data have shown that the combination of natedeline and ruxolitinib enhances apoptosis in MF patient-derived progenitor cells by lowering the apoptosis threshold (see, for example, Example 3 below). This combination utilizes complementary mechanisms converging on apoptotic cell death by inhibiting transient p21-mediated cell cycle arrest and the expression of pro-survival Bcl-2 family proteins (Clevenger 2023).

[0074] In vitro studies have demonstrated that the synergistic cytotoxicity of natedrine and ruxotinib (see, for example, Examples 2-8 below) is clinically relevant and associated with improved clinical outcomes. Natedrine, whether as monotherapy in study KRT-232-101A or as adjunctive therapy to ruxotinib in study KRT-232-109, reduced circulating CD34+ cells (see, for example, Examples 2-8 below). Figure 6A and Figure 6B -C). In both studies, the reduction in CD34+ cells was associated with SVR—patients with the largest decrease in peripheral CD34+ cell counts had the largest reduction in spleen volume. As previously discussed, spleen volume reduction was associated with increased OS and improved symptom severity (Mesa 2013; Vannucchi 2015). These results confirm the relevance of naledelin's cytotoxic mechanism in disease modification when used as adjunctive therapy to ruxolitinib, thereby improving outcomes in MF patients. Furthermore, this mechanism of action differs from and complements that of ruxolitinib monotherapy (e.g., inhibition of the JAK-STAT signaling pathway).

[0075] Furthermore, without being limited to any particular theory, MDM2 inhibition may have a beneficial effect on the addiction feedback loop between matrix / microenvironment cells and malignant clones in certain cases. Since p53 activation reduces NF-κB-mediated signaling, it may synergize with ruxolitinib (Lussana 2017; Greenfield 2018). When used in combination with JAK inhibition, natedrine-activated p53 may deprive malignant clones of their proliferative “niche” in the bone marrow and extramedullary hematopoietic sites. The synergistic anticancer effects suggest that natedrine as adjunctive therapy to ruxolitinib may be particularly beneficial for MF patients with a suboptimal response to ruxolitinib. Interim results from the ongoing KRT-232-109 study, as described in Examples 2-8, provide preliminary evidence of the efficacy of natedrine as adjunctive therapy to ruxolitinib, offering clinical support for the potential synergistic effects described above.

[0076] Clinical data Referring to reference box 202, in some embodiments, the method further includes obtaining clinical data involving multiple subjects 122 suffering from myeloproliferative neoplasms, wherein for each corresponding subject 122 among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements 124 prior to treatment with the first composition for myeloproliferative neoplasms and (ii) a corresponding first response set 126 following a first treatment period with the first composition. In some embodiments, the induction period is the first treatment period when the first composition is administered to a patient with myeloproliferative neoplasms.

[0077] In some embodiments, the method is performed on multiple subjects suffering from an indication (e.g., a clinical indication). In some embodiments, the first composition and / or the second composition are used for an indication (e.g., selected and / or used to treat an indication). In some embodiments, the method is performed to determine whether combined treatment with the first composition and the second composition improves one or more indication-related endpoints relative to monotherapy with the first composition.

[0078] In some implementations, the indication is myeloproliferative neoplasm. In some implementations, myeloproliferative neoplasm is myelofibrosis.

[0079] In some implementations, the indication is a disease, such as cancer. In some implementations, cancer includes breast cancer, lung cancer, prostate cancer, colorectal cancer, skin cancer, bladder cancer, blood cancer, leukemia, lymphoma, ovarian cancer, pancreatic cancer, kidney cancer, brain cancer, thyroid cancer, stomach (gastric) cancer, liver cancer, cervical cancer, esophageal cancer, bone cancer, sarcoma, and / or testicular cancer.

[0080] In some implementations, the indication is targeted at the stage of cancer, such as stage I, II, III, or IV of the tumor, lymph node, and distant metastasis (TNM) system.

[0081] In some embodiments, the corresponding first set of baseline measurements includes multiple baseline measurements. In some embodiments, the corresponding first set of baseline measurements includes at least 1, at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, or at least 200 baseline measurements. In some embodiments, the corresponding first set of baseline measurements includes no more than 500, no more than 200, no more than 100, no more than 50, no more than 10, or no more than 5 baseline measurements. In some embodiments, the corresponding first set of baseline measurements consists of 1 to 10, 2 to 20, 20 to 100, or 100 to 500 baseline measurements. In some embodiments, the corresponding first set of baseline measurements falls within another range starting with at least 1 baseline measurement and ending with no more than 500 baseline measurements.

[0082] In some implementations, the first set of baseline measurements includes one or more baseline measurements for each of the one or more endpoints.

[0083] In some embodiments, one or more endpoints include at least 1, at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, or at least 200 endpoints. In some embodiments, one or more endpoints include no more than 500, no more than 200, no more than 100, no more than 50, no more than 10, or no more than 5 endpoints. In some embodiments, one or more endpoints fall within another range starting with at least 1 endpoint and ending with no more than 500 endpoints.

[0084] In some embodiments, the first treatment period is greater than 5 weeks and less than 40 weeks. In some embodiments, the first treatment period is equal to or greater than 12 weeks and less than 36 weeks. In some embodiments, the first treatment period comprises daily administration of the first composition for at least 5 weeks without treatment interruption or dose adjustment. In some embodiments, the first treatment period comprises daily administration of the first composition for at least 8 weeks without treatment interruption or dose adjustment. In some embodiments, the active ingredient of the first treatment composition is ruxolitinib. Suitable embodiments for the first treatment period are further described elsewhere herein (see, for example, the section entitled "First Treatment and Second Treatment").

[0085] In some embodiments, the corresponding set of first reactions includes multiple first reactions. In some embodiments, the corresponding set of first reactions includes at least 1, at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, or at least 200 first reactions. In some embodiments, the corresponding set of first reactions includes no more than 500, no more than 200, no more than 100, no more than 50, no more than 10, or no more than 5 first reactions. In some embodiments, the corresponding set of first reactions consists of 1 to 10, 2 to 20, 20 to 100, or 100 to 500 first reactions. In some embodiments, the corresponding set of first reactions falls within another range starting with at least 1 first reaction and ending with no more than 500 first reactions.

[0086] In some implementations, the first reaction set includes one or more first reactions for each of the one or more endpoints.

[0087] In some implementations, one or more first baseline measurements, first responses, and / or endpoints are selected from any endpoints, inclusion criteria, and / or exclusion criteria disclosed herein (see, for example, the section entitled "Subjects" above and / or the section entitled "Endpoints" below).

[0088] Subjects In some implementations, the multiple subjects include 200 subjects. In some implementations, the multiple subjects include 500 subjects.

[0089] In some implementations, the multiple subjects include at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, or at least 10,000 subjects. In some implementations, the multiple subjects include no more than 100,000, no more than 10,000, no more than 5000, no more than 2000, no more than 1000, no more than 500, no more than 100, or no more than 50 subjects. In some implementations, the multiple subjects consist of 10 to 100, 80 to 500, 200 to 1000, 1000 to 10,000, or 10,000 to 100,000 subjects. In some implementations, the multiple subjects fall within another range: starting with at least 10 subjects and ending with no more than 100,000 subjects.

[0090] Reference box 204, in some implementations, multiple subjects are not treated with JAK inhibitors.

[0091] In some implementations, each subject in a plurality of subjects includes one or more inclusion criteria (e.g., in the corresponding first set of baseline measurements). In some implementations, one or more inclusion criteria are selected from any inclusion criteria listed in Table 1. In some implementations, each corresponding subject in a plurality of subjects includes at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten inclusion criteria listed in Table 1. In some implementations, each corresponding subject in a plurality of subjects includes all inclusion criteria listed in Table 1. In some implementations, each corresponding subject in a plurality of subjects includes no more than 14, no more than 10, no more than 8, no more than 5, or no more than 3 inclusion criteria listed in Table 1.

[0092] In some implementations, each of the multiple subjects does not meet one or more of the multiple exclusion criteria. In some implementations, the one or more exclusion criteria are selected from any of the exclusion criteria listed in Table 2. In some implementations, each corresponding subject in the multiple subjects includes at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least twenty, or at least thirty exclusion criteria listed in Table 2. In some implementations, each corresponding subject in the multiple subjects includes all of the exclusion criteria listed in Table 2. In some implementations, each corresponding subject in the multiple subjects includes no more than 41, no more than 30, no more than 20, no more than 10, no more than 8, no more than 5, or no more than 3 exclusion criteria listed in Table 2.

[0093] In some implementations, each of the multiple subjects has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 in the corresponding first set of baseline measurements. In some implementations, each of the multiple subjects has an ECOG performance status of 0, 1, 2, 3, or 4 in the corresponding first set of baseline measurements.

[0094] In some implementations, each of the multiple subjects has a baseline measurement of 450 cm or greater, as determined by magnetic resonance imaging or computed tomography, in the corresponding first set of baseline measurements. 3 The spleen measurement values.

[0095] In some implementations, each of the multiple subjects has a baseline measurement of at least 50, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, or at least 650 cm⁻¹, as determined by magnetic resonance imaging or computed tomography. 3 The spleen measurements. In some implementations, each of the multiple subjects has a spleen measurement value determined by magnetic resonance imaging or computed tomography that is no more than 700, no more than 600, no more than 500, no more than 400, no more than 300, no more than 200, or no more than 100 cm in the corresponding first set of baseline measurements. 3 The spleen measurements. In some implementations, each of the multiple subjects has a corresponding first set of baseline measurements ranging from 50 to 200, 100 to 300, 200 to 500, or 400 to 700 cm², determined by magnetic resonance imaging or computed tomography. 3 The spleen measurements. In some implementations, each of the multiple subjects has a spleen measurement that falls at least 50 cm from the starting point, as determined by magnetic resonance imaging or computed tomography, in the corresponding first set of baseline measurements. 3 And the end height is no higher than 700 cm 3 Another range of spleen measurements.

[0096] In some implementations, each of the multiple subjects has 100x10 in the corresponding first set of baseline measurements. 9 A platelet count of 1 / L or higher.

[0097] In some implementations, each of the multiple subjects has at least 50x10 in the corresponding first set of baseline measurements. 9 Units / L, at least 100x10 9 Units / L, at least 200x10 9 Units / L, at least 300 x 10 9 Units / L, at least 500 x 10 9 Units / L, at least 600x10 9 Units / L or at least 800 x 10 9 Platelet count per liter. In some implementations, each of the multiple subjects has a platelet count of no more than 1 x 10^6 cells / L in the corresponding first set of baseline measurements. 10 Units / L, not exceeding 800 x 10 9 Units / L, not exceeding 500 x 10 9 Units / L, not exceeding 300 x 10 9 Units / L, not exceeding 200 x 10 9Units / L or not exceeding 100x10 9 Platelet count per liter. In some implementations, each of the multiple subjects has a platelet count ranging from 50 x 10^6 / L in the corresponding first set of baseline measurements. 9 Units / L to 200x10 9 Units / L, from 100x10 9 Units / L to 500x10 9 Units / L, from 300x10 9 Units / L up to 800x10 9 Units / L or from 500x10 9 1 unit / L to 1x10 10 Platelet count of cells / L. In some implementations, each of the multiple subjects has a platelet count falling below 50 x 10⁻⁶ in the corresponding first set of baseline measurements. 9 1 unit / L and the end is not higher than 1x10 10 Platelet count in another range of 1 / L.

[0098] Table 1: Exemplary Inclusion Criteria Table 2: Exclusion Criteria for Examples Second-best response Referring to reference box 206, in some embodiments, the method further includes identifying subsets 122 of subjects, each of whom meets a suboptimal response threshold 132. In some embodiments, less than 80 percent of the subjects meet the suboptimal response threshold (e.g., the subset of subjects represents at least 20% of the subjects). In some embodiments, less than 40 percent of the subjects meet the suboptimal response threshold (e.g., the subset of subjects represents at least 60% of the subjects).

[0099] In some implementations, the subset of subjects includes at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, or at least 10,000 subjects. In some implementations, the subset of subjects includes no more than 100,000, no more than 10,000, no more than 5000, no more than 2000, no more than 1000, no more than 500, no more than 100, or no more than 50 subjects. In some implementations, the subset of subjects consists of 10 to 100, 80 to 500, 200 to 1000, 1000 to 10,000, or 10,000 to 100,000 subjects. In some implementations, the subset of subjects falls within another range starting with at least 10 subjects and ending with no more than 100,000 subjects.

[0100] In some implementations, the subset of subjects comprises at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, or at least 70% of multiple subjects. In some implementations, the subset of subjects comprises no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, or no more than 20% of multiple subjects. In some implementations, the subset of subjects comprises 10% to 40%, 20% to 60%, 30% to 70%, or 50% to 80% of multiple subjects. In some implementations, the proportion of the subset of subjects falls within another range of at least 10% and at least 80% of the total number of subjects.

[0101] In some implementations, the suboptimal response threshold is based on one or more indicators for each subject across multiple subjects. In some implementations, one or more indicators include a reduction in spleen size. In some implementations, a reduction in spleen size is a reduction in spleen volume (SVR). In some implementations, one or more indicators include the total symptom score (TSS). In some implementations, one or more indicators include any endpoints, inclusion criteria, and / or exclusion criteria disclosed elsewhere herein (see, for example, the section entitled "Subjects" above and / or the section entitled "Endpoints" below).

[0102] In some implementations, the corresponding first response set of a subject satisfies the suboptimal response threshold when (e.g., one or both of the following conditions are met): (i) the spleen size decreases by less than 35% (e.g., <35% SVR) between baseline measurements and the first treatment period, and / or (ii) the total symptom score decreases by 50% (e.g., <50% TSS reduction) between baseline measurements and the first treatment period. A negative SVR (e.g., -10%) indicates a 10% increase in spleen volume. A negative TSS decrease (e.g., -10%) indicates a 10% increase in TSS.

[0103] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when: (i) the spleen size decreases by less than 35% (e.g., <35% SVR) between baseline measurements and the first treatment period, and (ii) the total symptom score decreases by 50% (e.g., <50% TSS reduction) between baseline measurements and the first treatment period.

[0104] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than -25% and 35% (e.g., >-25% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than -35% and 50% (e.g., >-35% but <50% TSS).

[0105] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than -20% and 35% (e.g., >-20% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than -30% and 50% (e.g., >-30% but <50% TSS).

[0106] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than -15% and 35% (e.g., >-15% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than -25% and 50% (e.g., >-25% but <50% TSS).

[0107] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than -10% and 35% (e.g., >-10% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than -20% and 50% (e.g., >-20% but <50% TSS).

[0108] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than -5% and 35% (e.g., >-5% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than -15% and 50% (e.g., >-15% but <50% TSS).

[0109] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size reduction is between 0% and 35% (e.g., >0% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score reduction is between -5% and 50% (e.g., >-5% but <50% TSS).

[0110] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than 0% and 35% (e.g., >-15% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than 0% and 50% (e.g., >0% but <50% TSS).

[0111] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than 0% and 20% (e.g., >0% but <20% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than 0% and 30% (e.g., >0% but <30% TSS).

[0112] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by 20% or more and 35% (e.g., ≥20% but <35% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by 30% or more and 50% (e.g., ≥30% but <50% TSS).

[0113] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than 0% and 50% (e.g., >0% but <50% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than 0% and 70% (e.g., >0% but <70% TSS).

[0114] In some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between baseline measurements and after the first treatment period, the spleen size decreases by more than 0% and 40% (e.g., >0% but <40% SVR), and / or (ii) between baseline measurements and after the first treatment period, the total symptom score decreases by more than 0% and 60% (e.g., >0% but <60% TSS).

[0115] Reference box 208, in some implementations, the corresponding first response set of the subject satisfies the suboptimal response threshold when the following conditions are met (e.g., one or both conditions are met): (i) between the baseline measurement and the first treatment period, the spleen size reduction is between greater than 0% and 35% (e.g., >0% but <35% SVR), and / or (ii) between the baseline measurement and the first treatment period, the total symptom score reduction is between greater than 0% and 50% (e.g., >0% but <50% TSS).

[0116] In some implementations, the suboptimal response threshold for a corresponding subject's corresponding first response set is based on a comparison between each corresponding first response in one or more first responses of the first response set and a corresponding baseline measurement in a first set of baseline measurements. In some implementations, the one or more first responses used to determine whether the suboptimal response threshold is met are selected from any endpoints, inclusion criteria, and / or exclusion criteria disclosed herein (see, for example, the section entitled "Subjects" above and / or the section entitled "Endpoints" below).

[0117] In some implementations, the corresponding first response set of the corresponding subject satisfies the suboptimal response threshold based on a comparison between the corresponding first response of spleen size and the corresponding baseline measurement, wherein the comparison determines the reduction in spleen size between the baseline measurement and the period after the first treatment period.

[0118] In some embodiments, the spleen size reduction (e.g., SVR) is at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, or at least 70%. In some embodiments, the spleen size reduction is no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 3%. In some embodiments, the spleen size reduction is 1% to 20%, 10% to 40%, 25% to 60%, or 50% to 80%. In some embodiments, the spleen size reduction falls within another range, starting at a reduction of no less than 1% and ending at a reduction of no more than 80%. In some embodiments, the spleen size reduction is greater than 0%. In some embodiments, the spleen size reduction falls within another range, greater than 0% and no more than 80%.

[0119] Alternatively or additionally, in some embodiments, the corresponding first response set of the relevant subject satisfies a suboptimal response threshold based on a comparison between the corresponding first response and the corresponding baseline measurement using a total symptom score (TSS), wherein the total symptom score is determined using the Myelofibrosis Symptom Assessment Scale (MFSAF), and wherein a comparison determines a decrease in the total symptom score between the first baseline TSS measurement and the TSS after the first treatment period, or between the second baseline TSS measurement and the TSS after the second treatment period. In some embodiments, the first treatment period refers to a monotherapy period. In some embodiments, the first treatment period refers to a ruxotinib monotherapy period. In some embodiments, the second treatment period refers to a combination therapy period, in which the first composition and the second composition are administered to the patient simultaneously. In some embodiments, the second treatment period refers to a combination therapy period, in which the first composition and the second composition are administered to the patient simultaneously, wherein the first composition comprises ruxotinib; and the second composition comprises natedrine. See, for example, Mesa et al. The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis. Leuk Res. 2009 September ; 33(9):1199–1203. doi:10.1016 / j.leukres.2009.01.035, which is hereby incorporated in its entirety by reference.

[0120] In some embodiments, the TSS reduction is at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 50%, at least 60%, or at least 70%. In some embodiments, the TSS reduction is no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 3%. In some embodiments, the TSS reduction is 1% to 20%, 10% to 40%, 25% to 60%, or 50% to 80%. In some embodiments, the TSS reduction falls within another range, starting at a reduction of at least 1% and ending at a reduction of at least 80%. In some embodiments, the TSS reduction is greater than 0%. In some embodiments, the TSS reduction falls within another range, greater than 0% and no more than 80%. In some embodiments, comparing the corresponding second response set with the corresponding second group baseline TSS measurements obtained from the corresponding subjects prior to treatment with the combination of the first and second compositions, the TSS reduction is approximately 30%. In some embodiments, the TSS is reduced by approximately 35% compared to the baseline TSS measurement of the corresponding second group obtained from the corresponding subjects before treatment with the combination of the first and second compositions. In some embodiments, the TSS is reduced by approximately 40% compared to the baseline TSS measurement of the corresponding second group obtained from the corresponding subjects before treatment with the combination of the first and second compositions. In some embodiments, the TSS is reduced by approximately 45% compared to the baseline TSS measurement of the corresponding second group obtained from the corresponding subjects before treatment with the combination of the first and second compositions. In some embodiments, the TSS is reduced by approximately 50% compared to the baseline TSS measurement of the corresponding second group obtained from the corresponding subjects before treatment with the combination of the first and second compositions. In some embodiments, the TSS is reduced by approximately 55% compared to the baseline TSS measurement of the corresponding second group obtained from the corresponding subjects before treatment with the combination of the first and second compositions. In some implementations, the corresponding second response set is compared with the corresponding second group baseline TSS measurement obtained from the subject prior to combined treatment with the first and second compositions, and the TSS is reduced to approximately 60%.

[0121] In some embodiments, the TSS is reduced by approximately 30% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 35% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 40% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 45% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 50% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 55% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition. In some embodiments, the TSS is reduced by approximately 60% compared to the corresponding second-group baseline TSS measurement obtained from the corresponding subjects prior to treatment with the first composition.

[0122] The division between subjects and study arms.

[0123] Referring to reference box 209, in some embodiments, the method further includes randomizing a subset of subjects 122 into a first arm 134-1 and a second arm 134-2, wherein for a second treatment period, subjects 122 in the first arm 134-1 receive a combination of the first composition and the second composition, while subjects 122 in the second arm 134-2 receive a combination of the first composition and a placebo. In some embodiments, subjects are not divided, and the combination of the first composition and the second composition is administered to the subjects.

[0124] In some embodiments, the combination of the first composition and the second composition (also referred to herein as "combination therapy") includes receiving both the first and second compositions simultaneously. In some embodiments, the combination of the first and second compositions includes receiving both the first and second compositions sequentially. In some such embodiments, the first composition is received before the second composition. In some embodiments, the second composition is received before the first composition. In some embodiments, the first and second compositions are received sequentially without interruption (e.g., subsequent treatment is received immediately after the previous treatment has ceased). In some embodiments, subsequent treatment is not received immediately after the previous treatment has ceased, but rather some time after the previous treatment has ceased (e.g., 1 day or longer, 2 days or longer, 1 week or longer, between 1 day and 1 week, etc.). In some embodiments, the combination of the first and second compositions is received as "additional" treatment, wherein one of the first and second compositions is supplemented by the other of the first and second compositions after an initial treatment period. In some embodiments, "additional" treatment includes supplementing the first composition with the second composition during a second treatment period after a first treatment period with the first composition. In some embodiments, "additional" treatment includes supplementing the second composition with the first composition during a second treatment period after a first treatment period with the second composition. As will be apparent to those skilled in the art, any suitable method for combination therapy (e.g., simultaneous, sequential and / or additional) is considered for use in this disclosure.

[0125] In some implementations, the division of a subset of subjects into two or more arms is performed using stratification across one or more blocks. In some implementations, each block in the one or more blocks represents a stratification factor, score, and / or criterion, such as inclusion criteria or endpoint measures. In some implementations, the corresponding blocks in the one or more blocks are selected from any endpoint, inclusion criteria, and / or exclusion criteria disclosed herein (see, for example, the section entitled "Subjects" above and / or the section entitled "Endpoints" below).

[0126] In some implementations, randomization-based subgrouping of subjects into a first arm and a second arm is based on a stratified, permutation block randomization scheme that balances representativeness for each block in the first and second arms across multiple blocks, where the first block of the multiple blocks is rated as intermediate-1 on the International Prognostic Rating System (IPRS) and the second block of the multiple blocks is rated as intermediate-2 or high-risk on the IPSRS.

[0127] In some implementations, one or more blocks include stratification factors as International Prognostic Scoring System (IPSS) scores (e.g., intermediate-1, intermediate-2, and / or high-risk).

[0128] In some embodiments, one or more blocks include a stratification factor for the total daily dose (e.g., <20 mg vs. ≥20 mg) of the first treatment with the first composition.

[0129] In some implementations, the third block of a plurality of blocks is the total daily dose of the first treatment regimen that is below the threshold dose at the end of the first treatment regimen, and the fourth block of a plurality of blocks is the total daily dose of the first treatment regimen that is equal to or higher than the threshold dose at the end of the first treatment regimen.

[0130] In some implementations, the third block of a plurality of blocks is the total daily dose of the first treatment regimen that is equal to or lower than the threshold dose at the end of the first treatment regimen, and the fourth block of a plurality of blocks is the total daily dose of the first treatment regimen that is higher than the threshold dose at the end of the first treatment regimen.

[0131] In some embodiments, the threshold dose is at least 5, at least 10, at least 20, at least 30, or at least 40 mg. In some embodiments, the threshold dose is no more than 50, no more than 40, no more than 30, no more than 20, or no more than 10 mg. In some embodiments, the threshold dose is 5 to 20, 10 to 40, or 30 to 50 mg. In some embodiments, the threshold dose falls within another range, starting at a dose not less than 5 mg and ending at a dose not more than 50 mg. In some embodiments, the threshold dose is approximately 20 mg.

[0132] Alternatively or additionally, in some embodiments, randomizing a subset of subjects into a first arm and a second arm is based on a stratified randomization scheme that balances representativeness for each block in the first and second arms across a plurality of blocks, where each block corresponds to a particular response category. In some embodiments, the first block in the plurality of blocks is a first response range for a first response category (e.g., an endpoint), while the second block in the plurality of blocks is a second response range for the first response category (e.g., the endpoint). In some embodiments, the first response category is SVR. In some embodiments, the first response category is TSS reduction.

[0133] In some implementations, a first block of a plurality of blocks is a first response range for a first response category (e.g., a first endpoint), a second block of a plurality of blocks is a second response range for the first response category (e.g., a first endpoint), a third block of a plurality of blocks is a first response range for a second response category (e.g., a second endpoint), and a fourth block of a plurality of blocks is a second response range for a second response category (e.g., a second endpoint). In some implementations, the first response category is SVR, and the second response category is TSS reduction.

[0134] Referring to box 210, in some implementations, randomizing a subset of subjects into a first arm and a second arm is based on a stratified, permutation block randomization scheme that balances the representativeness of each block in the first and second arms across multiple blocks, where the first block of the multiple blocks is SVR > 0% but < 20%, and the second block of the multiple blocks is SVR ≥ 20% but < 35%. Referring to box 212, in some implementations, the third block of the multiple blocks is TSS reduction > 0% but < 30%, and the fourth block of the multiple blocks is TSS reduction ≥ 30% but < 50%.

[0135] As will be apparent to those skilled in the art, any number of response categories (e.g., SVR, TSS, etc.) and any number of ranges or strata within each response category (e.g., low, medium, high and / or any numerical range thereof) are considered for stratification and / or randomization of study arms in this disclosure. Furthermore, as will be apparent to those skilled in the art, response categories may be further subdivided into more or fewer blocks (e.g., strata) as needed to increase balanced representativeness at higher or lower resolutions.

[0136] Advantageously, and not limited by any operational theory, this approach mitigates the risk of treatment bias in some implementations (e.g., where the treatment response to additional naproxen is driven by a heavier weighting of subjects in the upper block of randomized SVR ≥ 30% but < 35%).

[0137] In some implementations, the multiple zones include at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 15 zones. In some implementations, the multiple zones include no more than 20, no more than 15, no more than 10, no more than 5, or no more than 3 zones. In some implementations, the multiple zones consist of 2 to 5, 3 to 8, 5 to 12, or 12 to 20 zones. In some implementations, the multiple zones fall within another range starting with at least 2 zones and ending with no more than 20 zones.

[0138] In some embodiments, multiple blocks correspond to at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 15 reaction categories (e.g., SVR, TSS). In some embodiments, multiple blocks correspond to no more than 20, no more than 15, no more than 10, no more than 5, or no more than 3 reaction categories. In some embodiments, multiple blocks correspond to 1 to 3, 2 to 5, 3 to 8, 5 to 12, or 12 to 20 reaction categories. In some embodiments, multiple blocks correspond to another group of reaction categories starting with at least 1 reaction category and ending with no more than 20 reaction categories.

[0139] In some implementations, for each corresponding reaction category in the set of reaction categories used for stratification, multiple blocks comprise corresponding subsets of blocks. In some implementations, the corresponding subset of blocks for a given reaction category comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 blocks. In some implementations, the subset of blocks comprises no more than 10, no more than 8, no more than 5, or no more than 3 blocks. In some implementations, the subset of blocks consists of 1 to 3, 2 to 5, 3 to 8, or 5 to 10 blocks. In some implementations, the subset of blocks falls within another range starting with at least 1 block and ending with no more than 10 blocks.

[0140] In some implementations, the first response category is stratified into the same or a different number of blocks as the second response category (e.g., SVR is stratified into 3 blocks, while TSS is stratified into 2 blocks). In some implementations, the corresponding response categories are stratified based on numerical ranges (e.g., percentage reductions), response types (e.g., the presence or extent of a suboptimal response), subject distribution (e.g., the percentage of a subject population falling within a range or response type), and / or any other stratification method that will be apparent to those skilled in the art.

[0141] In some implementations, the first arm comprises at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, or at least 10,000 subjects. In some implementations, the first arm comprises no more than 50,000, no more than 10,000, no more than 5000, no more than 2000, no more than 1000, no more than 500, no more than 100, or no more than 50 subjects. In some implementations, the first arm consists of 10 to 100, 80 to 500, 200 to 1000, 1000 to 10,000, or 10,000 to 50,000 subjects. In some implementations, the first arm falls within another range of starting with at least 10 subjects and ending with no more than 50,000 subjects.

[0142] In some implementations, the second arm comprises at least 10, at least 20, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 2000, at least 5000, or at least 10,000 subjects. In some implementations, the second arm comprises no more than 50,000, no more than 10,000, no more than 5000, no more than 2000, no more than 1000, no more than 500, no more than 100, or no more than 50 subjects. In some implementations, the second arm consists of 10 to 100, 80 to 500, 200 to 1000, 1000 to 10,000, or 10,000 to 50,000 subjects. In some implementations, the second arm falls within another range of starting with at least 10 subjects and ending with no more than 50,000 subjects.

[0143] In some embodiments, the first arm includes the same number of subjects as the second arm. In some embodiments, the first arm includes a larger number of subjects than the second arm. In some embodiments, the first arm includes a smaller number of subjects than the second arm. In some embodiments, the first arm includes twice or approximately twice the number of subjects as the second arm. In some embodiments, the first arm includes half or approximately half the number of subjects as the second arm.

[0144] In some embodiments, the method further includes, after identifying subsets of subjects from a plurality of subjects who each meet a suboptimal response threshold, and before dividing the subsets into a first arm and a second arm: for the first block (e.g., for a corresponding response category) of a plurality of blocks, restricting the subset of subjects such that the proportion of subjects represented by the first block in the subset of subjects is no greater than an inclusion threshold. In some embodiments, the first block is a spleen size reduction between 30% and 35%, and the inclusion threshold is 15%. In some embodiments, the first block is any response category, endpoint, or criterion disclosed herein. In some embodiments, the inclusion threshold is at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, or at least 30%. In some embodiments, the inclusion threshold is no more than 50%, no more than 30%, no more than 20%, no more than 15%, no more than 10%, or no more than 5%. In some embodiments, the inclusion threshold is 2% to 5%, 5% to 12%, 10% to 25%, 20% to 40%, or 25% to 50%. In some implementations, the enrollment threshold falls within another range: at the beginning, no less than 2%; and at the end, no more than 50%. In some illustrative implementations, the first block is the range of suboptimal response subjects with a SVR of ≥30% but <35%, and the limitation includes limiting the subject subset such that the proportion of subjects with an SVR of ≥30% but <35% does not exceed 15% of all enrolled suboptimal subjects.

[0145] Advantageously, and without being limited by any particular operational theory, in some implementations, enrollment quotas for one or more strata allow for clinically meaningful effects of the study design by aligning subject enrollment with the natural incidence and distribution of suboptimal responders. This further allows for improved balance of subject representation within the study and between different study groups.

[0146] First treatment period and second treatment period.

[0147] In some implementations, the first treatment period is greater than 5 weeks and less than 40 weeks. In some implementations, the first treatment period is equal to or greater than 12 weeks and less than 36 weeks.

[0148] In some implementations, the first treatment period is at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 2 months, at least 4 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, or at least 5 years. In some implementations, the first treatment period is no more than 10 years, no more than 5 years, no more than 2 years, no more than 1 year, no more than 6 months, no more than 4 months, no more than 2 months, no more than 4 weeks, or no more than 2 weeks. In some implementations, the first treatment period is 1 week to 2 months, 1 month to 6 months, 6 months to 1 year, 1 to 5 years, or 5 to 10 years. In some implementations, the first treatment period falls within another range: starting at at least 1 week and ending at no more than 10 years.

[0149] In some embodiments, the first treatment period comprises daily administration of the first composition for at least 5 weeks without treatment interruption or dose adjustment. In some embodiments, the first treatment period comprises daily administration of the first composition for at least 8 weeks without treatment interruption or dose adjustment. In some embodiments, the first treatment period comprises administration of the first composition without treatment interruption or dose adjustment for a period of at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 2 months, at least 4 months, at least 6 months, at least 1 year, or at least 2 years. In some embodiments, the administration period is no more than 3 years, no more than 2 years, no more than 1 year, no more than 6 months, no more than 4 months, no more than 2 months, no more than 4 weeks, or no more than 2 weeks. In some embodiments, the administration period is 2 weeks to 2 months, 1 month to 6 months, 6 months to 1 year, or 1 to 3 years. In some embodiments, the administration period falls within another range: starting at at least 2 weeks and ending at no more than 3 years.

[0150] In some implementations, the second treatment period is between 5 weeks and 100 weeks. In some implementations, the second treatment period is between 12 weeks and 200 weeks.

[0151] In some implementations, the second treatment period is at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 2 months, at least 4 months, at least 6 months, at least 1 year, at least 2 years, at least 5 years, or at least 10 years. In some implementations, the second treatment period is no more than 20 years, no more than 10 years, no more than 5 years, no more than 1 year, no more than 6 months, no more than 4 months, no more than 2 months, no more than 4 weeks, or no more than 2 weeks. In some implementations, the second treatment period is 1 week to 2 months, 1 month to 12 months, 1 to 5 years, 5 to 10 years, or 10 to 20 years. In some implementations, the second treatment period falls within another range: starting at at least 1 week and ending at no more than 20 years.

[0152] Reference box 214, in some embodiments, the active ingredient of the first therapeutic composition is ruxolitinib.

[0153] In some embodiments, a total daily dose of ruxotinib is administered to multiple subjects during the first and second treatment periods. In some embodiments, a total daily dose of ruxotinib is administered to multiple subjects during the first and second treatment periods. In some embodiments, a total daily dose of ruxotinib is administered to multiple subjects during the first and second treatment periods. In some embodiments, a total daily dose of ruxotinib of 2 to 10 mg is administered to multiple subjects during the first and second treatment periods.

[0154] In some embodiments, ruxolitinib is administered at a total daily dose of at least 1, at least 2, at least 5, at least 10, at least 20, or at least 30 mg. In some embodiments, ruxolitinib is administered at a total daily dose not exceeding 50, 30, 20, 10, or 5 mg. In some embodiments, ruxolitinib is administered at a total daily dose of 1 mg to 10 mg, 5 mg to 20 mg, or 20 mg to 50 mg. In some embodiments, ruxolitinib is administered at a total daily dose falling within another range, not less than 1 mg initially and not more than 50 mg at the end.

[0155] In some implementations, ruxolitinib is administered twice daily. In other implementations, ruxolitinib is administered once daily.

[0156] In some implementations, ruxolitinib is administered at least once a week, at least twice a week, at least three times a week, at least five times a week, at least once a day, at least twice a day, or at least three times a day. In some implementations, ruxolitinib is administered no more than four times a day, no more than twice a day, no more than once a day, no more than three times a week, or no more than twice a week. In some implementations, ruxolitinib is administered at a frequency of once to three times a week, three times a week to once a day, or once a day to four times a day. In some implementations, ruxolitinib is administered at a frequency falling within another range that begins at least once a week and ends at no more than four times a day.

[0157] Reference box 216, in some embodiments, the active ingredient of the second therapeutic composition is natedrine.

[0158] In some embodiments, during the second treatment period, each subject in the first arm is administered a total daily dose of ≥100 mg of nutedelin. In some embodiments, during the second treatment period, each subject in the first arm is administered a total daily dose of ≥200 mg of nutedelin. In some embodiments, during the second treatment period, each subject in the first arm is administered a total daily dose of nutedelin between 50 mg and 300 mg of nutedelin. In some embodiments, during the second treatment period, each subject in the first arm is administered a total daily dose of 240 mg of nutedelin.

[0159] In some embodiments, natedrine is administered in a total dose of at least 20, at least 50, at least 100, at least 200, at least 300, or at least 400 mg. In some embodiments, natedrine is administered in a total dose not exceeding 500, 300, 200, 100, or 50 mg. In some embodiments, natedrine is administered in a total dose ranging from 20 mg to 100 mg, 50 mg to 200 mg, or 200 mg to 500 mg. In some embodiments, natedrine is administered in a total dose range that begins at a minimum of 20 mg and ends at a maximum of 500 mg.

[0160] In some implementations, during the second treatment period, natedrine is administered twice daily to each subject in the first arm. In some implementations, during the second treatment period, natedrine is administered once daily to each subject in the first arm.

[0161] In some implementations, naledema is administered at least once a week, at least twice a week, at least three times a week, at least five times a week, at least once a day, at least twice a day, or at least three times a day. In some implementations, naledema is administered no more than four times a day, no more than twice a day, no more than once a day, no more than three times a week, or no more than twice a week. In some implementations, naledema is administered at a frequency of once to three times a week, three times a week to once a day, or once a day to four times a day. In some implementations, naledema is administered at a frequency falling within another range that begins at least once a week and ends at no more than four times a day.

[0162] Second reaction set and second baseline measurements.

[0163] Reference box 218, in some embodiments, the method further includes obtaining a corresponding second response set 138 for each corresponding subject 122 in the subject subset upon completion of the second treatment period.

[0164] In some embodiments, the corresponding set of second reactions includes multiple second reactions. In some embodiments, the corresponding set of second reactions includes at least 1, at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, or at least 200 second reactions. In some embodiments, the corresponding set of second reactions includes no more than 500, no more than 200, no more than 100, no more than 50, no more than 10, or no more than 5 second reactions. In some embodiments, the corresponding set of second reactions consists of 1 to 10, 2 to 20, 20 to 100, or 100 to 500 second reactions. In some embodiments, the corresponding set of second reactions falls within another range starting with at least 1 second reaction and ending with no more than 500 second reactions.

[0165] In some implementations, the second reaction set includes one or more second reactions for each of the one or more endpoints.

[0166] In some implementations, the method further includes obtaining corresponding second-group baseline measurements for the respective subjects after the subject subset is divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and a placebo.

[0167] In some embodiments, the corresponding second set of baseline measurements includes multiple baseline measurements. In some embodiments, the corresponding second set of baseline measurements includes at least 1, at least 2, at least 5, at least 10, at least 20, at least 50, at least 100, or at least 200 baseline measurements. In some embodiments, the corresponding second set of baseline measurements includes no more than 500, no more than 200, no more than 100, no more than 50, no more than 10, or no more than 5 baseline measurements. In some embodiments, the corresponding second set of baseline measurements consists of 1 to 10, 2 to 20, 20 to 100, or 100 to 500 baseline measurements. In some embodiments, the corresponding second set of baseline measurements falls within another range starting with at least 1 baseline measurement and ending with no more than 500 baseline measurements.

[0168] In some implementations, the second set of baseline measurements includes one or more baseline measurements for each of the one or more endpoints.

[0169] In some implementations, one or more second baseline measurements, second responses, and / or endpoints are selected from any endpoints, inclusion criteria, and / or exclusion criteria disclosed herein (see, for example, the section entitled “Subjects” above and / or the section entitled “Endpoints” below).

[0170] Evaluate Referring to box 219, in some embodiments, the method further includes evaluating each corresponding subject 122 in the subject subset by comparing the corresponding second response set 138 with (a) the corresponding first set of baseline measurements 124 of the corresponding subject 122 and / or (b) the optional corresponding second set of baseline measurements 136 obtained by the corresponding subject 122 after the subject subset is divided into a first arm 134-1 and a second arm 134-2 and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, thereby determining whether the combination of the first treatment and the second treatment in the first arm 134-1 improves one or more endpoints 142 associated with myeloproliferative neoplasms relative to 134-2 as a monotherapy with the first composition.

[0171] Reference box 220, in some implementations, each corresponding subject in a subset of subjects is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding first set of baseline measurements.

[0172] Referring to box 222, in some embodiments, the method further includes obtaining corresponding second-group baseline measurements for the respective subjects after the subject subset is divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and a placebo, and evaluating each respective subject in the subject subset by comparing the corresponding second-group baseline measurements with the corresponding second-group baseline measurements.

[0173] end.

[0174] In some implementations, one or more endpoints are common primary endpoints, secondary endpoints, or exploratory endpoints. In some implementations, one or more endpoints include common primary endpoints, secondary endpoints, and / or exploratory endpoints.

[0175] In some embodiments, one or more endpoints are selected from any of the endpoints listed in Table 3. In some embodiments, one or more endpoints include at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten endpoints listed in Table 3. In some embodiments, one or more endpoints include all the endpoints listed in Table 3. In some embodiments, one or more endpoints include no more than 13, no more than 10, no more than 8, no more than 5, or no more than 3 endpoints listed in Table 3.

[0176] In some embodiments, one or more endpoints are selected from any of the endpoints listed in Table 4. In some embodiments, one or more endpoints include at least one, at least two, at least three, at least four, or at least five endpoints listed in Table 4. In some embodiments, one or more endpoints include all the endpoints listed in Table 4. In some embodiments, one or more endpoints include no more than five, no more than four, no more than three, or no more than two endpoints listed in Table 4.

[0177] In some implementations, one or more endpoints include a reduction in spleen size. In some implementations, one or more endpoints include a reduction in spleen size as measured by magnetic resonance imaging (MRI) or computed tomography (CT) (e.g., a common primary endpoint).

[0178] In some implementations, one of the endpoints is a comparison of the following two: the proportion of subjects in the first arm whose spleen size reduction, as measured by magnetic resonance imaging or computed tomography, is greater than a spleen size reduction threshold between set times in the introduction and treatment periods, and the proportion of subjects in the second arm whose spleen size reduction, as measured by magnetic resonance imaging or computed tomography, is greater than a spleen size reduction threshold between set times in the introduction and treatment periods.

[0179] In some implementations, the first treatment period is between 12 and 36 weeks, and the second treatment period is set between 12 and 36 weeks after the start of the second treatment period. In some implementations, the first treatment period is between 12 and 36 weeks, and the second treatment period is set at 24 weeks after the start of the second treatment period.

[0180] In some implementations, the set time for the second treatment period is at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 2 months, at least 4 months, at least 6 months, at least 1 year, or at least 2 years after the start of the second treatment period. In some implementations, the set time for the second treatment period is no more than 3 years, no more than 2 years, no more than 1 year, no more than 6 months, no more than 4 months, no more than 2 months, no more than 4 weeks, or no more than 2 weeks after the start of the second treatment period. In some implementations, the set time for the second treatment period is 2 weeks to 2 months, 1 month to 6 months, 6 months to 1 year, or 1 to 3 years after the start of the second treatment period. In some implementations, the set time for the second treatment period falls within another range: a start date no less than 2 weeks and an end date no more than 3 years after the start of the second treatment period.

[0181] In some embodiments, the spleen size reduction threshold is a percentage between 25% and 50% of the first baseline spleen size measurement in the corresponding first set of baseline spleen size measurements. In some embodiments, the spleen size reduction threshold is at least 35% of the first baseline spleen size measurement in the corresponding first set of baseline measurements. In some embodiments, the spleen size reduction threshold is a percentage between 25% and 50% of the second baseline spleen volume measurement in the corresponding second set of baseline spleen volume measurements. In some embodiments, the spleen size reduction threshold is at least 35% of the second baseline spleen volume measurement in the corresponding second set of baseline spleen volume measurements.

[0182] In some embodiments, the spleen size reduction threshold is a reduction of at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, or at least 70%. In some embodiments, the spleen size reduction threshold is a reduction of no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 3%. In some embodiments, the spleen size reduction threshold is 1% to 20%, 10% to 40%, 25% to 60%, or 50% to 80%. In some embodiments, the spleen size reduction threshold falls within another range where the reduction begins at a minimum of 1% and ends at a minimum of 80%.

[0183] In some implementations, one or more endpoints include an improvement in the quality of life score (e.g., total symptom score) between the first and second arms (e.g., a co-primary endpoint). In some implementations, one or more endpoints include a reduction in the total symptom score (TSS) or the TSS thereof.

[0184] In some implementations, one of the endpoints is a comparison of the following two: the proportion of subjects in the first arm showing an improvement in quality of life assessment scores greater than a threshold amount between the set time periods of the induction and treatment periods, and the proportion of subjects in the second arm showing an improvement in quality of life assessment scores greater than a threshold amount between the set time periods of the induction and treatment periods.

[0185] In some implementations, the first treatment period is between 12 and 36 weeks, and the second treatment period is set between 12 and 36 weeks after the start of the second treatment period. In some implementations, the first treatment period is between 12 and 36 weeks, and the second treatment period is set at 24 weeks after the start of the second treatment period.

[0186] In some implementations, the set time for the second treatment period is at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 2 months, at least 4 months, at least 6 months, at least 1 year, or at least 2 years after the start of the second treatment period. In some implementations, the set time for the second treatment period is no more than 3 years, no more than 2 years, no more than 1 year, no more than 6 months, no more than 4 months, no more than 2 months, no more than 4 weeks, or no more than 2 weeks after the start of the second treatment period. In some implementations, the set time for the second treatment period is 2 weeks to 2 months, 1 month to 6 months, 6 months to 1 year, or 1 to 3 years after the start of the second treatment period. In some implementations, the set time for the second treatment period falls within another range: a start date no less than 2 weeks and an end date no more than 3 years after the start of the second treatment period.

[0187] In some implementations, for subjects in a subset of subjects: the corresponding first set of baseline measurements includes a first score derived from a quality of life assessment scale, the corresponding second response set includes a second score derived from a quality of life assessment scale, and the improvement in quality of life assessment scores between set times in the induction and second treatment periods is the difference between the first and second scores.

[0188] In some implementations, the quality of life assessment form is the Myelofibrosis Symptom Assessment Form or the Myeloproliferative Neoplasia Symptom Assessment Form v2.0. In some implementations, the quality of life assessment form is the General Quality of Life Questionnaire (EQ-5D), eHEALS, the EORTC QLG Core Questionnaire (EORTC QLQ-C30), the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale (e.g., the Promis Fatigue Questionnaire), and / or the Patient Activation Scale (PAM-13).

[0189] In some implementations, the quality of life assessment scale is the Myeloproliferative Neoplasm Symptom Assessment Scale v4.0 (MFSAFv4.0). MFSAF-TSS v4.0 consists of seven items that measure symptoms associated with MPN disease, including fatigue (tiredness, exhaustion), night sweats (or feeling hot or flushed), itching, abdominal discomfort (feeling of pressure or bloating), pain under the left rib, a feeling of fullness after starting to eat, and bone pain (non-articular or arthritic pain). Each item is rated on a scale of 0 (none) to 10 (the most severe conceivable). MFSAF-TSS is calculated as the sum of observed symptoms. Therefore, the possible score range for MFSAF v4.0 is 0 to 70.

[0190] The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.

[0191] The PROMIS Fatigue Questionnaire measures the frequency of a range of symptoms, from mild subjective fatigue to overwhelming, debilitating, and persistent fatigue, using seven questions. Each question uses a 5-point scale, with scores ranging from 1 (never) to 5 (always).

[0192] In some implementations, the quality of life assessment scale is the Patient General Impression Change (PGIC). The PGIC consists of a single question and is intended to measure a patient's perception of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale, where 1 equals significant improvement and 7 equals significant deterioration.

[0193] In some embodiments, the quality of life assessment form is a myeloproliferative neoplasm symptom assessment form (e.g., v2.0 and / or v4.0), and the improvement threshold is a reduction of at least 60 percent in the quality of life assessment score. In some embodiments, the quality of life assessment form is a myeloproliferative neoplasm symptom assessment form (e.g., v2.0 and / or v4.0), and the improvement threshold is a reduction of at least 50 percent in the quality of life assessment score.

[0194] In some implementations, the reduction in the quality of life assessment score is at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, or at least 70%. In some implementations, the reduction in the quality of life assessment score is no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 3%. In some implementations, the reduction in the quality of life assessment score is 1% to 20%, 10% to 40%, 25% to 60%, or 50% to 80%. In some implementations, the reduction in the quality of life assessment score falls within another range, starting at a reduction of no less than 1% and ending at a reduction of no more than 80%.

[0195] In some implementations, one or more endpoints include overall survival metrics (e.g., secondary endpoints).

[0196] In some implementations, one of the endpoints is a comparison of a first overall survival value calculation with a second overall survival value calculation, wherein the first overall survival value calculation is a central tendency measure of the difference between the following two factors across the first arm of the subject: (i) time of enrollment during the introductory period, and (ii) time of death from any cause, and the second overall survival value calculation is a central tendency measure of the difference between the following two factors across the second arm of the subject: (i) time of enrollment during the introductory period, and (ii) time of death from any cause.

[0197] In some implementations, overall survival (OS) is defined as the time from the enrollment date at the introductory phase to the date of death from any cause. In some implementations, subjects who have not died before the data analysis cutoff date are censored based on their last known survival date before the cutoff date. In some implementations, subjects known to be alive or dead after the data cutoff date are censored at the data cutoff date. In some implementations, a stratified log-rank test adjusted for stratification factors is used to compare OS between the first and second arms.

[0198] In some implementations, the central tendency measure is the mean, median, mode, weighted mean, weighted median, and / or weighted mode.

[0199] In some implementations, one or more endpoints include progression-free survival metrics (e.g., secondary endpoints).

[0200] In some implementations, one of the endpoints is a comparison of a first progression-free survival (PFS) value calculation with a second PFS value calculation, wherein: the first PFS value calculation is a central tendency measure of the difference between the following two for subjects across the first arm: (i) enrollment time during the introductory period, and (ii) the time when (a) spleen size exceeds a threshold percentage of spleen volume relative to spleen size at the start of the introductory period, (b) leukemia transformation, or (c) the first occurrence of death from any cause; while the second PFS value calculation is a central tendency measure of the difference between the following two for subjects across the second arm: (i) enrollment time during the introductory period, and (ii) the time when (a) spleen size increases by a threshold amount (e.g., threshold percentage of spleen volume) relative to spleen size at the start of the introductory period, (b) leukemia transformation, or (c) the first occurrence of death from any cause.

[0201] In some embodiments, the threshold percentage spleen volume is 15% to 35% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 25% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 15% to 35% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 25% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements.

[0202] In some embodiments, the threshold percentage spleen volume is at least 1%, at least 2%, at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 60%, or at least 70% (e.g., relative to a first or second baseline spleen volume measurement). In some embodiments, the threshold percentage spleen volume is no more than 80%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10%, no more than 5%, or no more than 3% (e.g., relative to a first or second baseline spleen volume measurement). In some embodiments, the threshold percentage spleen volume is 1% to 20%, 10% to 40%, 25% to 60%, or 50% to 80% (e.g., relative to a first or second baseline spleen volume measurement). In some embodiments, the threshold percentage spleen volume falls within another range, starting at no less than 1% and ending at no more than 80% (e.g., relative to a first or second baseline spleen volume measurement).

[0203] In some implementations, leukemic transformation includes: (i) an increase of ≥20% in bone marrow blast count compared to the bone marrow blast count at enrollment during the induction period, with a blast count exceeding 1x10 for at least 2 weeks. 9 The absolute blast cell count per L was correlated with (ii) a blast cell count of more than 1 x 10⁻⁶ cells / L, and / or (ii) a blast cell count in peripheral blood that was ≥20% higher than the blast cell count at the time of enrollment during the induction period, and that was sustained for at least 2 weeks. 9 This is correlated with the absolute primitive cell count per L.

[0204] In some implementations, the bone marrow blast count is at least 10%, at least 20%, at least 30%, or at least 50% higher than the bone marrow blast count at the entry-in period. In some implementations, the bone marrow blast count is no more than 60%, no more than 50%, no more than 40%, no more than 30%, or no more than 20% higher than the bone marrow blast count at the entry-in period. In some implementations, the bone marrow blast count is 10% to 20%, 20% to 40%, or 40% to 60% higher than the bone marrow blast count at the entry-in period. In some implementations, the range of increase in bone marrow blast count compared to the entry-in period falls within another range of at least 10% at the beginning and no more than 60% at the end. Alternatively or additionally, in some implementations, the bone marrow blast count at the entry-in period is at least 10x10⁻¹⁰. 8 Units / L, at least 100x10 8 Units / L, at least 1x10 9 Units / L or at least 10x10 9 The absolute blast cell count per L is associated with the number of cells / L. In some implementations, the bone marrow blast cell count at enrollment during the introduction phase is not more than 100 x 10⁻⁶ cells / L. 9Units / L, not exceeding 10x10 9 Units / L, not exceeding 1x10 9 Units / L or not exceeding 100x10 8 The absolute blast cell count per L is correlated. In some implementations, the bone marrow blast cell count at enrollment during the introduction phase is correlated with 10 x 10⁻⁶ cells / L. 8 1 unit / L to 1x10 9 Units / L, 1x10 9 Units / L to 10x10 9 Units / L or 10x10 9 Units / L to 100x10 9 The absolute blast cell count per L is associated with the number of cells / L. In some implementations, the bone marrow blast cell count at enrollment during the introduction phase is associated with a starting count of at least 10 x 10⁻⁶ cells / L. 8 100 x 10⁻⁶ cells / L and the end value is not higher than 100 x 10⁻⁶ cells / L. 9 This is correlated with the absolute primitive cell count in another range of cells / L.

[0205] In some implementations, the central tendency measure is the mean, median, mode, weighted mean, weighted median, and / or weighted mode.

[0206] In some implementations, one or more endpoints include the duration of spleen response between the first and second arms (e.g., a secondary endpoint).

[0207] In some implementations, one of the endpoints is a comparison of a first mean time duration with a second mean time duration, wherein the first mean time duration is between (i) the time at which spleen size reduction of at least a threshold percentage of spleen volume is first observed after the induction period, and (ii) the time at which disease progression or death is observed in subjects across the first arm; and the second mean time duration is between (i) the time at which spleen size reduction of at least a threshold percentage is first observed after the induction period, and (ii) the time at which disease progression or death is observed in subjects across the second arm.

[0208] In some embodiments, the threshold percentage spleen volume is 35% to 45% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 35% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 35% to 45% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is 35% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements. In some embodiments, the threshold percentage spleen volume is any value of the threshold percentage spleen volume disclosed elsewhere herein.

[0209] In some implementations, one or more endpoints include improvement in spleen size between the first and second arms, such as as measured by palpation (e.g., a secondary endpoint).

[0210] In some implementations, one of the endpoints is a comparison of the following two: the proportion of subjects in the first arm whose spleen size reduction, as measured by palpation, is greater than a spleen size reduction threshold between set times in the introduction and treatment periods, and the proportion of subjects in the second arm whose spleen size reduction, as measured by palpation, is greater than a spleen size reduction threshold between set times in the introduction and treatment periods.

[0211] In some implementations, the corresponding first set of baseline measurements includes first measurements of the corresponding subject organs, while the corresponding second set of responses includes second measurements of the corresponding subject organs.

[0212] In some implementations, the organ is the spleen of the corresponding subject.

[0213] In some implementations, the first measurement of the corresponding subject organ is the first measurement of the size of the corresponding subject's spleen, and the second measurement of the corresponding subject organ is the second measurement of the size of the corresponding subject's spleen.

[0214] This disclosure considers various methods for measuring the spleen, including measuring spleen length by palpation and / or measuring spleen volume by imaging.

[0215] In some implementations, spleen length is assessed by palpation and measured in centimeters (cm) using a ruler. The spleen's edges are determined by palpation, and its length is measured from the lower left costal margin to the point of greatest splenic prominence.

[0216] In some embodiments, one or more endpoints include secondary efficacy endpoints. In some embodiments, secondary efficacy endpoints are determined by comparing the corresponding second response set with corresponding second set baseline measurements obtained from the respective subjects after the subject subset was divided into the first arm and the second arm and before treatment with the combination of the first composition and the second composition or the combination of the first composition and placebo (e.g., between pre-randomization baseline and post-randomization period).

[0217] In some embodiments, one or more endpoints are primary or secondary efficacy endpoints selected from SVR25, TSS30, SVR35, and TSS50, determined by comparing the corresponding second response set with the corresponding first group baseline measurement prior to treatment with the first composition and the corresponding second group baseline measurement obtained from the respective subjects prior to treatment with the combination of the first and second compositions or the combination of the first composition and placebo. SVR25 measures the proportion of subjects in each study arm whose SVR is ≥ 25% after the second treatment period relative to the start of the second treatment period. TSS30 measures the proportion of subjects in each study arm whose TSS is ≥ 30% after the second treatment period relative to the start of the second treatment period. SVR35 measures the proportion of subjects in each study arm whose SVR is ≥ 35% after the second treatment period relative to the start of the first treatment period. TSS50 measures the proportion of subjects in each study arm whose TSS is ≥ 50% after the second treatment period relative to the start of the first treatment period. In some embodiments, SVR25 is a reduction in spleen volume of more than 25% after the second treatment period relative to the start of the second treatment period. In some embodiments, SVR35 is a reduction in spleen volume of more than 35% relative to the start of the first treatment period after the second treatment period. In some embodiments, TSS30 is a reduction in total symptom score of more than 30% relative to the start of the second treatment period after the second treatment period. In some embodiments, TSS50 is a reduction in total symptom score of more than 50% relative to the start of the first treatment period after the second treatment period. In some embodiments, the first treatment period refers to a monotherapy period. In some embodiments, the first treatment period refers to a ruxotinib monotherapy period. In some embodiments, the second treatment period refers to a combination therapy period, wherein the first composition and the second composition are administered to the patient simultaneously. In some embodiments, the second treatment period refers to a combination therapy period, wherein the first composition comprises ruxotinib; the second composition comprises natedelin.

[0218] In some implementations, the common primary endpoints are SVR25, TSS30, SVR35, and TSS50. In some implementations, the common primary endpoints are SVR25 and TSS30. In some implementations, the common primary endpoints are SVR35 and TSS50. In some implementations, the common primary endpoints are SVR25 and SVR35. In some implementations, the common primary endpoints are TSS30 and TSS50.

[0219] In some embodiments, the endpoints are SVR25 and SVR35, wherein SVR25 is determined by comparing the corresponding second response set with the corresponding second set of baseline spleen volume measurements obtained in the corresponding subject prior to combined treatment with the first composition and the second composition; wherein SVR35 is determined by comparing the corresponding second response set with the corresponding first set of baseline spleen volume measurements obtained in the corresponding subject prior to treatment with the first composition. In some embodiments, the endpoints are TSS30 and TSS50; wherein TSS30 is determined by comparing the corresponding second response set with the corresponding second set of baseline TSS measurements obtained in the corresponding subject prior to combined treatment with the first composition; wherein TSS50 is determined by comparing the corresponding second response set with the corresponding first set of baseline TSS measurements obtained in the corresponding subject prior to treatment with the first composition. In some implementations, the endpoints are SVR25, SVR35, TSS30, and TSS50; wherein SVR25 and TSS30 are determined by comparing the corresponding second response set with corresponding second set baseline measurements obtained on the respective subjects prior to combined treatment with the first composition and the second composition; wherein SVR35 and TSS50 are determined by comparing the corresponding second response set with corresponding first set baseline measurements obtained on the respective subjects prior to treatment with the first composition.

[0220] Table 3: Exemplary Endpoints In some implementations, one or more endpoints include bone marrow biopsy (e.g., by pathological review). In some implementations, one or more endpoints include endpoints for assessing cancer. In some implementations, one or more endpoints include the percentage of blast cells in the bone marrow, myelofibrosis grade, bone marrow cellular composition, myeloid-to-erythroid ratio in the bone marrow, and / or other changes in bone marrow histological characteristics.

[0221] In some embodiments, one or more endpoints include the evaluation of one or more biomarkers as listed in Table 4. In some embodiments, one or more endpoints include the evaluation of one, two, three, four, five, or six or more biomarkers listed in Table 4.

[0222] Table 4: Exemplary Biomarker Evaluation Abbreviations: ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity); EOT (End of Treatment).

[0223] Additional endpoint In some implementations, the contribution effect of natedrin will be characterized relative to historical SVR and TSS response thresholds.

[0224] In some implementations, one or more endpoints include multi-component endpoints. In some implementations, one or more endpoints are common primary multi-component endpoints.

[0225] In some embodiments, a multi-component endpoint includes multiple component endpoints. In some embodiments, each corresponding component endpoint in the multiple component endpoints includes any endpoint disclosed herein (see, for example, the “Endpoints” section above). In some embodiments, the multiple component endpoints include at least 2, at least 3, at least 4, at least 5, at least 6, or at least 10 component endpoints. In some embodiments, the multiple component endpoints include no more than 20, no more than 10, no more than 5, or no more than 3 component endpoints. In some embodiments, the multiple component endpoints consist of 2 to 5, 3 to 8, 5 to 12, or 10 to 20 component endpoints. In some embodiments, the multiple component endpoints fall within another range starting with at least 2 component endpoints and ending with no more than 20 component endpoints.

[0226] In some embodiments, the multi-component endpoint includes at least the total symptom score. In some embodiments, the multi-component endpoint includes two or more total symptom scores. In some embodiments, the multi-component endpoint includes a reduction in spleen volume. In some embodiments, the multi-component endpoint includes multiple reductions in spleen volume.

[0227] In some implementations, the multi-component endpoints include: one or more total symptom scores, one or more changes in spleen volume, and / or one or more quality of life scores.

[0228] In some implementations, the multi-component endpoint includes spleen volume reduction (SVR) that meets the following threshold values: at least ≥5% (SVR5), at least ≥10% (SVR10), at least ≥15% (SVR15), at least ≥20% (SVR20), at least ≥25% (SVR25), at least ≥30% (SVR30), at least ≥35% (SVR35), at least ≥40% (SVR40), at least ≥45% (SVR45), at least ≥50% (SVR50), at least ≥55% (SVR55), at least ≥60% (SVR60), at least ≥65% (SVR65), at least ≥70% (SVR70), at least ≥75% (SVR75), at least ≥80% (SVR80), at least ≥85% (SVR85), at least ≥90% (SVR90), at least ≥95% (SVR95), or at least ≥100% (SVR100).

[0229] In some implementations, the multi-component endpoint includes a total symptom score (TSS) that meets the following threshold values: at least ≥5% (TSS5), at least ≥10% (TSS10), at least ≥15% (TSS15), at least ≥20% (TSS20), at least ≥25% (TSS25), at least ≥30% (TSS30), at least ≥35% (TSS35), at least ≥40% (TSS40), at least ≥45% (TSS45), at least ≥50% (TSS50), at least ≥55% (TSS55), at least ≥60% (TSS60), at least ≥65% (TSS65), at least ≥70% (TSS70), at least ≥75% (TSS75), at least ≥80% (TSS80), at least ≥85% (TSS85), at least ≥90% (TSS90), at least ≥95% (TSS95), or at least ≥100% (TSS100).

[0230] In some implementations, the multi-component endpoint includes any combination of the spleen volume reduction (SVR) and total symptom score (TSS) thresholds (e.g., SVR25 and TSS30).

[0231] In some implementations, the component endpoint among multiple component endpoints is measured as a comparison between the second reaction set and the first set of baseline measurements.

[0232] In some embodiments, the second response set is obtained from the first arm of subjects after treatment with the first and second compositions (e.g., after treatment with ruxotinib and nuxoside following randomization). In some embodiments, the first composition is ruxotinib. In some embodiments, the second composition comprises ruxotinib and nuxoside, wherein ruxotinib and nuxoside are administered to the patient, respectively. In some embodiments, ruxotinib and nuxoside are administered to the patient at different intervals or dosing regimens. In some embodiments, the second response set is obtained from the second arm of subjects after treatment with the first composition and placebo (e.g., after treatment with ruxotinib and placebo following randomization). In some embodiments, baseline measurements for the first group are obtained from each of multiple subjects prior to any treatment (e.g., at pre-ruxotinib baseline). For example, in some embodiments, a component endpoint among multiple component endpoints is measured as a comparison between post-randomization treatment and pre-ruxotinib baseline.

[0233] In some implementations, the component endpoint among multiple component endpoints is measured as a comparison between a second reaction set and a second set of baseline measurements.

[0234] In some embodiments, the second response set is obtained from the first arm of subjects after treatment with the first and second compositions (e.g., after treatment with ruxotinib and natedeline following randomization). In some embodiments, the second response set is obtained from the second arm of subjects after treatment with the first composition and placebo (e.g., after treatment with ruxotinib and placebo following randomization). In some embodiments, the second set of baseline measurements is obtained from each of the multiple subjects after randomization (e.g., after a subset of subjects is divided into the first and second arms) and before treatment following randomization (e.g., before any treatment following treatment with the combination of the first and second compositions or the combination of the first composition and placebo) (e.g., pre-randomization baseline). For example, in some embodiments, a component endpoint among multiple component endpoints is measured as a comparison between post-randomization treatment and pre-randomization baseline.

[0235] In some implementations, one or more endpoints are the proportion of patients who achieve any of the following SVR endpoints from a second-group baseline measurement (e.g., pre-randomization baseline): ≥5% (SVR5), ≥10% (SVR10), ≥15% (SVR15), ≥20% (SVR20), ≥25% (SVR25), ≥30% (SVR30), ≥35% (SVR35), ≥40% (SVR40), ≥45% (SVR45), ≥50% (SVR50), ≥55% (SVR55), ≥60% (SVR60), ≥65% (SVR65), ≥70% (SVR70), ≥75% (SVR75), ≥80% (SVR80), ≥85% (SVR85), ≥90% (SVR90), ≥95% (SVR95), and ≥100%. (SVR100), and any of the following SVR endpoints from the first set of baseline measurements (e.g., the baseline before ruxolitinib): ≥5% (SVR5), ≥10% (SVR10), ≥15% (SVR15), ≥20% (SVR20), ≥25% (SVR25), ≥30% (SVR30), ≥35% (SVR35), ≥40% (SVR40), ≥45% (SVR45), ≥50% (SVR50), ≥55% (SVR55), ≥60% (SVR60), ≥65% (SVR65), ≥70% (SVR70), ≥75% (SVR75), ≥80% (SVR80), ≥85% (SVR85), ≥90% (SVR90), ≥95% (SVR95), and ≥100% (SVR100).

[0236] In some implementations, one or more endpoints are the proportion of patients who achieve any of the following TSS reduction endpoints from a second-group baseline measurement (e.g., pre-randomization baseline): ≥5% (TSS5), ≥10% (TSS10), ≥15% (TSS15), ≥20% (TSS20), ≥25% (TSS25), ≥30% (TSS30), ≥35% (TSS35), ≥40% (TSS40), ≥45% (TSS45), ≥50% (TSS50), ≥55% (TSS55), ≥60% (TSS60), ≥65% (TSS65), ≥70% (TSS70), ≥75% (TSS75), ≥80% (TSS80), ≥85% (TSS85), ≥90% (TSS90), ≥95% (TSS95), and ≥100%. (TSS100), and any of the following TSS reduction endpoints from the first set of baseline measurements (e.g., baseline before ruxolitinib): ≥5% (TSS5), ≥10% (TSS10), ≥15% (TSS15), ≥20% (TSS20), ≥25% (TSS25), ≥30% (TSS30), ≥35% (TSS35), ≥40% (TSS40), ≥45% (TSS45), ≥50% (TSS50), ≥55% (TSS55), ≥60% (TSS60), ≥65% (TSS65), ≥70% (TSS70), ≥75% (TSS75), ≥80% (TSS80), ≥85% (TSS85), ≥90% (TSS90), ≥95% (TSS95), and ≥100% (TSS100).

[0237] In some implementations, spleen volume reduction (SVR) will be evaluated (e.g., by MRI / CT scan) at any of the following time stages after randomization: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 2... 4 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 1 year, 1.25 years, 1.5 years, 1.75 years, and 2 years.

[0238] In some implementations, the total symptom score (TSS) will be assessed at any of the following time points after randomization (e.g., using the Myelofibrosis Symptom Assessment Scale (MFSAF)). v4.0): 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, 27 weeks, 28 weeks, 29 weeks, 30 weeks, 31 weeks, 32 weeks, 33 weeks, 34 weeks, 35 weeks, 36 weeks, 37 weeks, 38 weeks, 39 weeks, 40 weeks, 41 weeks, 42 weeks, 43 weeks, 44 weeks, 45 weeks, 46 weeks, 47 weeks, 48 ​​weeks, 49 weeks, 50 weeks, 51 weeks, 52 weeks, 1 year, 1.25 years, 1.5 years, 1.75 years, and 2 years.

[0239] In some implementations, the assessment of symptom benefit will be supported by assessments from multiple parallel anchoring scales (e.g., changes in patient overall impression) collected during randomization (e.g., within a clinical trial study).

[0240] In some implementations, one or more endpoints are the proportion of patients who achieved SVR ≥ 25% (SVR25) from their baseline before randomization and SVR ≥ 35% (SVR35) from their baseline before ruxolitinib.

[0241] In some implementations, one or more endpoints are the proportion of patients who achieved a TSS reduction of ≥ 30% (TSS30) from the baseline before randomization and a TSS reduction of ≥ 50% (TSS50) from the baseline before ruxolitinib.

[0242] In some implementations, one or more endpoints are response thresholds such as SVR25 and TSS30 measured from the baseline before randomization, used to demonstrate the contribution effect of natedrin.

[0243] In some implementations, one or more endpoints are response thresholds measured from a second set of baseline measurements (e.g., the pre-randomization baseline), said thresholds being any of the following: SVR5, SVR10, SVR15, SVR20, SVR25, SVR30, SVR35, SVR40, SVR45, SVR50, SVR55, SVR60, SVR65, SVR70, SVR75, SVR80, SVR85, SVR90, SVR95 and SVR100, and any of the following: TSS5, TSS10, TSS15, TSS20, TSS25, TSS30, TSS35, TSS40, TSS45, TSS50, TSS55, TSS60, TSS65, TSS70, TSS75, TSS80, TSS85, TSS90, TSS95 and TSS100, are used to demonstrate the contributing effect of the second composition (e.g., natadeline).

[0244] In some implementations, for an SVR or TSS responder to be considered as being in multiple subjects or subsets thereof (e.g., a clinical trial study), each subject in the multiple subjects or subsets thereof meets in vivo thresholds determined for both the first set of baseline measurements and the second set of baseline measurements (e.g., meeting any multi-component or component endpoint thresholds disclosed above for both the baseline before randomization and the baseline before ruxolitinib).

[0245] In some implementations, multiple component endpoints in a multi-component endpoint include component endpoints determined at a first time point (e.g., before ruxolitinib monotherapy) and a second time point (e.g., a later time point after randomization to add atedrin or placebo).

[0246] In some implementations, one or more endpoints are defined as follows: before ruxolitinib monotherapy, at week 18 (when determining whether a subject is a suboptimal responder), and at week 24 after randomization to add nutdrine or placebo.

[0247] In some embodiments, the endpoint and / or component endpoints in a multi-component endpoint include a central tendency measure of any endpoint disclosed herein. In some embodiments, the central tendency measure is the mean, median, mode, weighted mean, weighted median, and / or weighted mode. In some embodiments, the endpoint and / or its component endpoints include an average SVR that meets any of the above thresholds. In some embodiments, the endpoint and / or its component endpoints include, for example, an average TSS that meets any of the above thresholds. In some embodiments, the endpoint and / or its component endpoints include an additional improvement in the threshold central tendency measure relative to the respective endpoint and / or component endpoint. In some embodiments, for example, an additional 25% SVR plus an 18% average SVR would result in an effective response threshold of 39% from the pre-ruxolitinib baseline.

[0248] Additional Implementation Plan Another aspect of this disclosure includes a computing system comprising a computer memory configured to store clinical data. In some embodiments, the clinical data pertains to multiple subjects suffering from myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition or with the second composition for myeloproliferative neoplasms, and (ii) a corresponding first set of responses following the first treatment period with the first composition.

[0249] In some implementations, the computing system also includes one or more processors that communicate with computer memory and are configured to execute program instructions to perform a method.

[0250] In some implementations, the method includes identifying subsets of subjects from a plurality of subjects, each meeting a suboptimal response threshold. In some implementations, the method further includes randomizing the subsets of subjects into a first arm and a second arm, wherein, for a second treatment period, subjects in the first arm receive a combination of the first composition and the second composition, while subjects in the second arm receive a combination of the first composition and a placebo.

[0251] In some implementations, for each corresponding subject in the subset of subjects, the method further includes obtaining a corresponding second response set upon completion of the second treatment period; and assessing each corresponding subject in the subset of subjects by comparing the corresponding second response set with (a) a corresponding first set of baseline measurements for the corresponding subject and / or (b) optional corresponding second set of baseline measurements obtained for the corresponding subject after the subset of subjects was divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, thereby determining whether the combination of the first treatment and the second treatment in the first arm improved one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition.

[0252] In some embodiments, each subject in a subset of subjects is evaluated by comparing a corresponding second response set of the corresponding subject with a corresponding first set of baseline measurements. In some embodiments, the method further includes obtaining a corresponding second set of baseline measurements for the corresponding subject after the subset of subjects has been divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, and evaluating each subject in the subset of subjects by comparing a corresponding second response set of the corresponding subject with a corresponding second set of baseline measurements.

[0253] Another aspect of this disclosure includes a non-transitory computer-readable storage medium storing instructions that, when executed by a computer system, cause the computer system to perform a method for determining whether combined treatment with a first composition and a second composition improves one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition.

[0254] In some embodiments, the method includes obtaining clinical data involving multiple subjects suffering from myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition and (ii) a corresponding first set of responses after a first treatment period with the first composition. In some embodiments, the method further includes identifying subsets of subjects among the multiple subjects, each of whom meets a suboptimal response threshold.

[0255] In some embodiments, the method further includes randomizing a subset of subjects into a first arm and a second arm, wherein for the second response period, subjects in the first arm receive a combination of the first composition and the second composition, while subjects in the second arm receive a combination of the first composition and a placebo. In some embodiments, the method further includes obtaining a corresponding second response set for each subject in the subset of subjects upon completion of the second treatment period.

[0256] In some implementations, the method further includes assessing each corresponding subject in the subject subset by comparing the corresponding second response set with (a) the corresponding first group baseline measurements of the corresponding subject and / or (b) optional corresponding second group baseline measurements obtained by the corresponding subject after the subject subset is divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, thereby determining whether the combination of the first treatment and the second treatment in the first group improves one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition.

[0257] In some embodiments, each subject in a subset of subjects is evaluated by comparing a corresponding second response set of the corresponding subject with a corresponding first set of baseline measurements. In some embodiments, the method further includes obtaining a corresponding second set of baseline measurements for the corresponding subject after the subset of subjects has been divided into a first arm and a second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, and evaluating each subject in the subset of subjects by comparing a corresponding second response set of the corresponding subject with a corresponding second set of baseline measurements.

[0258] Another aspect of this disclosure includes a system comprising a memory; one or more processors; and one or more modules stored in the memory and configured to be executed by the one or more processors, said one or more modules including instructions for performing any of the methods disclosed herein.

[0259] Another aspect of this disclosure includes a non-transitory computer-readable storage medium storing one or more programs for execution by one or more processors of a computer system, the one or more computer programs including instructions for performing any of the methods disclosed herein. Example

[0260] Example 1 – Evaluation of the effect of natedeline + ruxolitinib compared to placebo + ruxolitinib on the efficacy of ruxolitinib A randomized, double-blind study of safety and efficacy in patients with superior response to myelofibrosis. This is a phase 3, randomized, double-blind, placebo-controlled study of atedrin or placebo as adjunctive therapy to ruxolitinib in MF patients who had a suboptimal response after ≥18 weeks of ruxolitinib monotherapy.

[0261] Subjects with myofascial fever who have not received JAKi treatment will be enrolled in the ruxolitinib monotherapy induction phase. Figure 3 It meets the suboptimal reaction criteria and has TP53. WT Participants in the MF study will be randomized in a double-blind, placebo-controlled manner to receive either natedeline or placebo as adjunctive therapy to ruxolitinib. Each part of the study design is described below.

[0262] Approximately 630 JAKi-naïve patients with myofascial fever (MF) are expected to be enrolled, with 180 randomized suboptimal response subjects (Harrison 2012; Verstovsek 2012; Mesa 2017). Subjects will receive ruxolitinib monotherapy during the lead-up period at an investigator-selected dose of ≥5 mg twice daily (BID). After ≥18 weeks and <25 weeks of treatment, response to therapy will be evaluated in subjects with a stable ruxolitinib dose for ≥6 consecutive weeks (e.g., ≥5 mg BID, without interruption or dose adjustment). Subjects with a suboptimal response to stable-dose ruxolitinib monotherapy and meeting eligibility criteria (including a stable ruxolitinib dose for ≥8 consecutive weeks) will be randomized in a double-blind, placebo-controlled manner to receive either natedrine or placebo as adjunctive therapy to ruxolitinib. Note that the randomization baseline is set at a stable ruxolitinib dose for ≥8 consecutive weeks; however, in some implementations, response assessment is permitted earlier during the lead-up period after a stable dose for ≥6 consecutive weeks.

[0263] The second-best response to ruxolitinib monotherapy was defined as a reduction in spleen volume >0% but <35% as measured by MRI / CT scan (central review). as well asTSS reduction via MFSAF v4.0 was >0% but <50%. Subjects who did not meet the randomization criteria could continue receiving commercially available ruxolitinib as standard treatment and would discontinue the study.

[0264] Approximately 180 evaluable subjects with a suboptimal response to ruxolitinib monotherapy will be randomized in a 2:1 ratio to receive either nutedrin as adjunctive therapy to ruxolitinib (N = 120; first arm) or placebo as adjunctive therapy to ruxolitinib (N = 60; second arm). Nutedrin / placebo will be administered at 240 mg once daily on days 1–7 of a 28-day treatment cycle, and will not be administered on days 8–28 of the 28-day treatment cycle.

[0265] Throughout both treatment arms, ruxolitinib will continue to be administered at the subject's stable dose (e.g., a dose of ≥5 mg BID that does not require interruption or dose adjustment within 8 weeks prior to treatment in the randomization phase). For each subject, no dose escalation or any increase to a dose higher than the stable dose during randomization is permitted prior to the primary efficacy assessment.

[0266] Treatment allocation will be performed using a stratified, permutation block randomization scheme, based on one or more (e.g., at least four) stratification factors: - SVR > 0% but < 20%; - SVR ≥ 20% but < 35%; - TSS decreased by >0% but <30%; - TSS decreased by ≥30% but <50%; - Optionally, the International Prognostic Scoring System (IPSS; (Cervantes 2009)) (intermediate risk -1 versus intermediate risk -2 or high risk); and / or - Optionally, the total daily dose of ruxolitinib during randomization (<20 mg vs. ≥20 mg).

[0267] A radiological assessment of the disease will be conducted at a designated time.

[0268] The study will include a screening period, an induction period, and a randomization and follow-up period for eligible participants.

[0269] Screening assessments will be conducted within 28 days prior to the start of the induction period. Subjects who meet all eligibility criteria are eligible to enroll in the study.

[0270] The introductory period will begin on day 1 of cycle 1 with ruxolitinib monotherapy and continue until randomization to natedeline / placebo as an adjunct to ruxolitinib, or until the study ends for subjects who are ineligible to participate in the randomization period.

[0271] The randomization period consists of a 28-day cycle and will begin with the first dose of additional study treatment during the study period of natedeline / placebo and continue until the end of treatment (EOT) visit (which should be performed within 28 days of the last dose of study drug). Natedeline / placebo treatment should be initiated as soon as possible after randomization approval or within 3 days. During the randomization period, all subjects will continue study treatment until the criteria for permanent discontinuation of the study drug are met. These criteria include disease progression, intolerance to the study drug, or study termination. Efficacy assessments will be performed, including but not limited to SVR25, TSS30, SVR35, and / or TSS50.

[0272] The follow-up period will begin when the subject stops treatment during the randomization period and will continue until death, loss to follow-up, withdrawal of consent, or end of the study, whichever occurs first. The follow-up period may include response follow-up and long-term follow-up.

[0273] The response follow-up period will be conducted for randomized subjects who discontinue treatment for reasons other than disease progression, and efficacy will be assessed at least every 12 weeks ± 7 days until disease progression, withdrawal of consent, or initiation of subsequent anticancer treatment.

[0274] The long-term follow-up period will be conducted on randomized subjects who experience disease progression. These subjects will be followed up every 12 weeks ± 14 days for survival and subsequent anticancer treatment until the end of the study.

[0275] Example 2 – The combination of natedeline and ruxolitinib synergistically increases apoptosis in the JAK2 V617F cell line In the UKE-1 cell line (a type of TP53 derived from patients with primary thrombocytopenic purpura who transformed into acute leukemia) WT JAK2 V617F Apoptosis induced by natedrine, ruxolitinib, or their combination was evaluated in cell lines (Fiedler2000). Addition of ruxolitinib to natedrine synergistically increased apoptosis at 24 hours (P<0.001) (data not shown). Quantitative comparisons of combination versus monotherapy results were performed using Combeneft software, employing the highest single-agent (HSA) model, demonstrating a statistically significant synergistic effect at clinically meaningful concentrations (Clevenger 2023).

[0276] Example 3 – The combination of natedeline and ruxolitinib has a synergistic effect on apoptosis of progenitor cells derived from patients with chronic phase MF. Same effect Because the UKE-1 cell line cannot fully represent myeloid cells in chronic myelofibrosis (since the MF cell line is TP53), MUT(Since it was unavailable for use), the combination effect was validated in myeloid cells from MF patients. The efficacy of natedrine and ruxolitinib was evaluated in an apoptosis assay using peripheral blood mononuclear cells collected from chronic phase MF patients. MF cells were co-cultured with a matrix support layer to more closely mimic the supportive signals from the tumor microenvironment present in vivo.

[0277] After co-culturing for 24 and 72 hours, progenitor cells (CD45) were identified by flow cytometry in the presence of clinically relevant concentrations of atedrin, ruxolitinib, or a combination of both drugs. +mid SSC low CD14 - The study examined apoptosis markers (lysed PARP). The combination of natedrine and ruxolitinib induced significantly more apoptosis in MF progenitor cells at 72 hours than either drug alone. Figure 4 A).

[0278] Activation of p53 also activates p21, a key cell cycle checkpoint induced by p53, which regulates cell cycle arrest and antagonizes apoptosis. As expected, naltedinine alone significantly increased p21 expression in MF patient cells, while ruxolitinib alone did not. Unexpectedly, the combination of naltedinine and ruxolitinib significantly reduced naltedinine-induced p21 activation levels, which was evident 24 hours after initial exposure. Compared to naltedinine alone, p21 expression was almost completely suppressed at 72 hours of combined exposure. Figure 4 B). These results indicate that MF patient cells treated with the combination of naltetracycline and ruxolitinib still induced p21 activation, but were at a significantly reduced apoptosis threshold required to overcome p21-mediated cell cycle arrest and apoptosis resistance. Surprisingly, in addition to the reduced apoptosis threshold in MF cells, another synergistic mechanism of this combination was observed—significantly reduced expression of the Bcl-2 family protein MCL-1, an important pro-survival and cell death escape pathway utilized by cancer cells in myeloid and B-cell diseases. Figure 5 ).

[0279] Example 4 – Cytotoxicity and Splenic Effects of Natedeline as Monotherapy or as Add-on Therapy to Ruxotinib Volume reduction related In MF, there are no “true” cytotoxic targets that define clinical response at the blast cell level, as in AML. However, in vitro results showed that natedelin robustly reduced circulating CD34 both as monotherapy in study KRT-232-101A (see study design in Example 6) and as adjunctive therapy to ruxolitinib in study KRT-232-109 (Example 7). + Cells (shown separately) Figure 6A and Figure 6B-C). Importantly, in both studies, CD34 + The reduction in cells was associated with SVR—peripheral CD34 + The patients with the greatest decrease in cell count also had the largest reduction in spleen volume.

[0280] In the KRT-232-101A study, subjects who received 240 mg of treatment on days 1–7 of a 28-day treatment cycle from baseline cycle 1 to week 24 had circulating CD34 levels. + The median reduction in cells was 89.02% (range: -98.5% to 103.7%; (Vachhani 2021)). Analysis of all evaluable subjects indicated that CD34... + Changes in cell count were significantly positively correlated with the degree of SVR (Severe Cell Retention). Figure 6A ).

[0281] In the KRT-232-109 study, continuous ruxotinib treatment plus atedral reduced CD34 levels at both weeks 12 and 24. + Cell counts, with a greater median decrease at week 24. Figure 6B In fact, from day 1 of baseline cycle 1 to week 24, CD34 + Four of the five subjects with the largest reductions were SVR35 responders. Figure 6C ).

[0282] These results provide compelling evidence that naturedlin-induced malignant CD34 + Cellular cytotoxicity improved the clinically important outcome of SVR and established the relevance of cytotoxic mechanisms in disease modification outcomes in MF patients. Furthermore, these results further support the relevance of MF cell-killing models, demonstrating synergistic effects in preclinical trials (see, for example, Examples 2 and 3). Importantly, this cytotoxicity-mediated mechanism differs from and complements the mechanism of action of ruxolitinib monotherapy (e.g., inhibition of the JAK-STAT signaling pathway).

[0283] Example 5 – KRT-232-114: The efficacy of natadeline monotherapy in untreated myelofibrosis KRT-232-114 was a phase 2 open-label study evaluating the safety and efficacy of natedrine monotherapy in treatment-naïve patients with myocardial infarction (MF). A total of 14 subjects were treated with natedrine 240 mg on days 1–7 of a 28-day cycle. The median duration of treatment was 183.0 days (range: 7–539). At week 24, 14.3% of subjects (2 / 14) had a ≥35% SVR at the central review, while 28.6% (4 / 14) had a ≥50% TSS reduction at the same time point via MFSAF v4.0.

[0284] Example 6 – KRT-232-101A: Natedeline monotherapy in ruxolitinib-relapsed / refractory myelofibrosis Chemicals have therapeutic effects and lead to disease modification. KRT-232-101A is a phase 2, open-label, dose-exploration study designed to evaluate the safety and efficacy of nutedelin in subjects with relapsed or refractory myocardial infarction (MF) treated with JAK inhibitors. Subjects were treated with one of four dosing regimens to determine the optimal phase 2 dose and regimen: nutedelin 120 mg QD on days 1–7 of a 21-day cycle; nutedelin 240 mg QD on days 1–7 of a 21-day cycle; nutedelin 240 mg QD on days 1–7 of a 28-day cycle; or nutedelin 240 mg QD on days 1–5 of a 28-day cycle.

[0285] A total of 32 subjects were treated with naltetracycline 240 mg on days 1–7 of a 28-day cycle. Fourteen (14) of these subjects had experienced ≥28 days of ruxolitinib washout prior to baseline imaging assessment; efficacy outcomes were reported for this subset of patients to control for the effect on spleen following discontinuation of ruxolitinib prior to day 1 of cycle 1. The median duration of treatment for all 32 subjects was 175.5 days (range: 2–469). At week 24 assessment, 14.3% of subjects (2 / 14) had a ≥35% SVR at central review, while 14.3% (2 / 14) had a ≥50% TSS reduction at the same time point via MFSAF v4.0.

[0286] Natedeline monotherapy leads to disease modification in MF. Pharmacodynamic (PD) analysis showed that treatment with natedeline modifies disease, including CD34. + Decreased cell count and decreased VAF.

[0287] CD34 + Decreased cell count CD34 + Decreased cell counts are associated with progression-free survival (PFS) and overall survival (OS). Figure 7 (Vachhani 2023). CD34 +Subjects whose cell counts returned to normal (e.g., <7 cells / μL) had significantly longer CD34 counts than those with CD34. + PFS and OS in subjects with persistently elevated cell counts.

[0288] Driver gene VAF decreases: In all evaluable subjects, the optimal reduction in VAF was significantly positively correlated with the optimal change in spleen volume (p<0.001). (This is in contrast to CD34.) + Similarly, the decrease in VAF is related to PFS and OS. Figure 8 (Vachhani 2023). Subjects with a VAF reduction of ≥20% had longer PFS and longer OS compared to subjects with a VAF reduction of <20%.

[0289] Improvement in myelofibrosis: Of all evaluable subjects, 27.3% (12 / 44) showed improvement in fibrosis grade from baseline to week 24.

[0290] Example 7 – KRT-232-109: Synergistic Effect of Continuous Treatment with Stable-Dose Ruxotinib Plus Natedeline therapeutic response KRT-232-109 is an ongoing Phase 1 / 2 study investigating the safety and efficacy of nutedrin as adjunctive therapy to ruxotinib in patients with myasthenia gravis (MF) who had a suboptimal response to ruxotinib monotherapy. Eligible patients had no splenic response according to IWG-MRT criteria and showed no signs of progression following prior stable-dose ruxotinib treatment. In the Phase 1 dose escalation study, subjects were treated with nutedrin 120 mg, 180 mg, or 240 mg on days 1–7 of a 28-day cycle. In the Phase 2 dose extension phase, additional subjects were treated with the recommended Phase 2 dose (RP2D) of 240 mg on days 1–7 of a 28-day treatment cycle. As of May 2, 2023, a total of 28 subjects had received RP2D. Subjects had previously received prior ruxotinib monotherapy before being added to nutedrin, with a median duration of 21.6 months (range: 7–129). Importantly, it was noted that no ruxotinib dose was increased in any subject after initiation of natedrine. The median duration of treatment with natedrine as adjunctive therapy to a stable dose of ruxotinib was 143 days (range: 3–449). Nineteen (19) subjects reached week 24 or discontinued treatment prior to that point and were eligible for efficacy evaluation. At week 24 evaluation, a total of 31.6% (6 / 19) of the subjects had a ≥35% SVR (supplementary virological response rate) assessed by central review. Figure 9 ), while 31.6% (6 / 19) had a TSS reduction of ≥50% at the same time point via MFSAF v4.0 ( Figure 10 ).

[0291] The addition of ruxolitinib to natedrine resulted in disease modification of myofascitis (MF). Add-on therapy with ruxolitinib and natedrine reduced the driver gene VAF and improved myelofibrosis score. Figure 11 Of the 7 evaluable subjects, 71% (5 out of 7) experienced a ≥20% reduction in the driver gene VAF at week 24, while 57% (4 out of 7) showed improvement in myelofibrosis score at both baseline and week 24. These preliminary results represent a significant improvement compared to changes observed at similar time points in studies of ruxolitinib (Kvasnicka 2018) or natedrine monotherapy.

[0292] Example 8 – Clinical evidence of the synergistic effect of continuous ruxolitinib therapy combined with atedrin When comparing results from the natedeline monotherapy studies KRT-232-114 and KRT-232-101A with the adjunctive study KRT-232-109, clinical evidence of a synergistic effect of adding natedeline to ruxolitinib was demonstrated (Table 5). The results indicate that natedeline as an adjunct to continuous ruxolitinib therapy is superior to the efficacy achieved by natedeline alone, as measured by SVR and TSS reduction.

[0293] In studies KRT-232-114 and KRT-101A, patients with ruxotinib-naïve or ruxotinib-relapsed / refractory MF were treated with natedrine monotherapy. In each of these studies, 14.3% of patients treated with natedrine monotherapy had a splenic response (SVR ≥ 35%) at week 24. In KRT-232-109, patients who did not have a splenic response according to IWG-MRT criteria and had no disease progression during ruxotinib monotherapy, but received a stable dose of ruxotinib for ≥ 8 weeks (median duration of ruxotinib monotherapy was 21.6 months), received natedrine as adjunctive therapy to their continued ruxotinib treatment. In this study, 31.6% of patients had an SVR ≥ 35% and TSS ≥ 50% at week 24, significantly better than the responses reported in the natedrine monotherapy studies KRT-232-114 and KRT-232-101A.

[0294] Table 5: Clinical evidence of the synergistic effect of natedeline and ruxolitinib Abbreviations: Rux = Ruxotinib; SVR35 = Spleen volume reduction ≥35% at week 24; TSS50 = Total symptom score reduction ≥50% at week 24. Natedeline dosage: All natedeline administrations are 240 mg on days 1-7 of a 28-day cycle.

[0295] Notably, the new SVR ≥35% and TSS ≥50% responses occurred in patient populations where continued ruxolitinib monotherapy did not provide further response benefit, as SVR and TSS responses to ruxolitinib plateaued after the initial 12 weeks of ruxolitinib monotherapy (Verstovsek 2012). Therefore, the efficacy outcomes observed in study KRT-232-109 are attributed to the addition of nutedelin to continued ruxolitinib therapy. In summary, these clinical results strongly support further development of nutedelin as an adjunct therapy to ruxolitinib in patients with a suboptimal response to ruxolitinib monotherapy in study KRT-232-115. Furthermore, the response magnitude following the addition of nutedelin to continued ruxolitinib therapy (31.6% of patients had SVR ≥35%) exceeded that observed in monotherapy trials (14.3% in both first-line and relapsed / refractory settings), approximately 2.2 times, strongly suggesting a synergistic effect in this combination.

[0296] Treatment with ruxolitinib plus atedral resulted in a new SVR ≥35%, however, many other subjects had a clinically relevant reduction in spleen volume of ≥25% to <35%. Figure 9 While numerically less than SVR ≥ 35%, SVR ≥ 25% was associated with a clinically significant increase in overall survival. A pooled analysis of results from COMFORT-1 and COMFORT-2 reported that SVR ≥ 25% was associated with a meaningful improvement in survival, similar in magnitude to the improvement associated with SVR ≥ 35% (Vannucchi 2015). In the pooled analysis, the survival hazard ratio for patients treated with ruxolitinib with SVR ≥ 25% to < 35% was 0.25 (95% CI: 0.11–0.61), representing a 75% reduction in the risk of death compared to patients with SVR < 10%. Most importantly, this hazard ratio was numerically similar to that for patients achieving SVR ≥ 35% to < 50% (0.24 [95% CI: 0.11–0.56]).

[0297] In the KRT-232-109 study, the addition of natedrine did not negatively affect ruxolitinib administration. Reduction of the ruxolitinib dose before week 24 was rare, occurring in only 15.8% (3 / 19) of patients, and all three patients achieved at least a 25% reduction in spleen volume at week 24. This provides clinical evidence that ruxolitinib dose reduction did not negatively impact the patient's ability to obtain additional clinical benefit.

[0298] The safety profile of ruxolitinib-additional atrazine as adjunctive therapy in study KRT-232-109 was acceptable. Serious adverse events (SAEs) occurred in 19.4% of participants, with atrazine-related SAEs occurring in 8.3% of participants. Anemia was the only SAE occurring in >1 participants (occurring in 2 participants, 5.6%). Grade 3 / 4 TEAEs related to atrazine were reported in 44.4% of participants. The most frequently reported Grade 3 / 4 TEAEs related to atrazine (>5%) were thrombocytopenia / low platelet count (25%), anemia (13.9%), nausea (11.1%), diarrhea, low neutrophil count, and leukocytosis (5.6% each).

[0299] Example 9 – Study KRT-232-115: A comparison of naltetracycline + ruxotinib versus placebo + ruxotinib in… Safety and efficacy in myelofibrosis patients who had not received JAK inhibitor therapy and had a suboptimal response to ruxotinib (3) Randomized double-blind supplementary study This study includes a ≥18-week but <25-week ruxolitinib monotherapy induction period during which subjects will receive standard ruxolitinib treatment. Upon completion of the induction period, eligible subjects identified as having a suboptimal response to ruxolitinib monotherapy will be randomized 2:1 in a double-blind, placebo-controlled manner to receive either additional natedeline (arm 1) or additional placebo (arm 2) on top of continued ruxolitinib treatment. All subjects assessed as having a refractory or best response to ruxolitinib monotherapy will be discontinued from the study.

[0300] The lead-in period will begin with the initiation of ruxotinib monotherapy and continue until randomization to atedrin / placebo as adjunctive therapy to ruxotinib (or until study termination for subjects ineligible for randomization). During the lead-in period, eligible JAK inhibitor-naïve MF subjects will receive ruxotinib monotherapy at a dose of ≥5 mg twice daily (BID), at the investigator's discretion. Spleen volume and MF symptoms will be assessed in subjects who have received stable ruxotinib at a dose of ≥5 mg BID for ≥6 consecutive weeks (i.e., dose ≥5 mg BID without interruption or dose adjustment) around ≥18 weeks but <25 weeks of ruxotinib monotherapy. These assessments should be performed within 14 days prior to randomization.

[0301] The randomization period consists of a 28-day treatment cycle and will begin from the first dose of supplemental nutedrine / placebo until the end-of-treatment (EOT) visit (to be performed within 28 days of the last dose of study drug). Approximately 180 eligible subjects identified as having a suboptimal response to ruxolitinib will be randomized (2:1) in a double-blind, placebo-controlled manner to receive supplemental nutedrine (arm 1; n = 120) or supplemental placebo (arm 2; n = 60) in addition to continued ruxolitinib therapy. A suboptimal response to ruxolitinib monotherapy is defined as a spleen volume reduction of >0% but <35% as measured by MRI / CT scan (central review). as well as TSS reduction with MFSAF v4.0 >0% but <50%. Key eligibility requirements are that subjects must have received a stable dose of ruxolitinib for ≥8 consecutive weeks (note that response assessment is permitted during the monotherapy introduction period after a stable dose for ≥6 consecutive weeks) and have… TP53 WT MF. Subjects who do not meet the randomization criteria will be discontinued from the study and may continue to receive commercially available ruxolitinib according to the standard of care.

[0302] A study involving multiple subjects (Study KRT-232-115) will measure spleen size and symptoms in JAKi-naïve MF patients at three key time points: before treatment with the first combination therapy (e.g., before ruxolitinib monotherapy), at a second time point after the first treatment period (e.g., at least week 18 (when determining whether the subject is a suboptimal responder)), and at a third time point after the second treatment period (e.g., 24 weeks after randomization to add-on natedrine or add-on placebo). Efficacy assessments will be performed, including but not limited to SVR25, TSS30, SVR35, and / or TSS50. This unique study design allows for the assessment of the contribution effect of combinations of the first and second compositions, or combinations of the first composition and placebo (e.g., with or without natedrine), by comparing a multi-component endpoint comprising two component endpoints, SVR25 and TSS30, with established SVR35 and TSS50 thresholds from both within-patient and overall population perspectives. The component endpoints are determined as such based on a comparison of the second response set with baseline measurements in the second group (e.g., from pre-randomization baseline). The multi-component endpoint ensures that only patients who achieve SVR35 or TSS50 in the first group baseline measurements (e.g., from ruxolitinib pre-baseline) are defined as responders if they also achieve SVR25 and TSS30 in the second group baseline measurements (e.g., from pre-randomization baseline), thereby attributing a clinically meaningful benefit within the patient based on established thresholds. Figure 12 , Figure 13In a preferred embodiment, the multi-component endpoint includes: 1. the proportion of patients with a baseline SVR ≥ 25% (SVR25) before randomization and a baseline SVR ≥ 35% (SVR35) before ruxotinib; and 2. the proportion of patients with a baseline TSS reduction ≥ 30% (TSS30) before randomization and a baseline TSS reduction ≥ 50% (TSS50) before ruxotinib.

[0303] The multi-component spleen response endpoint based on spleen volume reduction was shown at... Figure 12 Patients achieving a SVR35 (spleen volume reduction ≥35%) from pre-ruxolitinib baseline were defined as responders (even though they achieved an SVR25 (spleen volume reduction ≥25%) from pre-randomization baseline). The multi-component spleen response endpoint based on spleen volume reduction was shown on... Figure 13 Patients who achieved a TSS50 (≥50% reduction in total symptom score) from the baseline before ruxolitinib were defined as responders (even though they achieved a TSS30 (≥30% reduction in total symptom score) from the baseline before randomization).

[0304] In summary, the multi-component co-primary endpoint will isolate the contribution of additional natedeline, while ensuring that the extent of spleen and symptom benefit is clinically meaningful from the perspective of the established SVR35 and TSS50 endpoints.

[0305] Consistency analysis of SVR25 and TSS30 with SVR35 and TSS50 A three-step approach was adopted to correlate response thresholds SVR25 and TSS30, as measured from the baseline before randomization, with historical thresholds SVR35 and TSS50 (e.g., from the baseline before ruxolitinib) for clinically meaningful benefits in JAKi-naïve individuals.

[0306] first step: Data were pooled from publicly available phase 3 studies (Verstovsek 2012; Mesa 2017; Pemmaraju 2023; Rampal 2023) of patients with MF in a JAKi-naïve setting treated with ruxolitinib to understand the natural history of MF patients who achieved a suboptimal response to ruxolitinib (e.g., subjects with SVR > 0% but < 35% and TSS reduction > 0% but < 50%) as defined in study KRT-232-115. Figure 14 ).

[0307] Figure 14The second-best responders for spleen and symptoms from pooled phase 3 ruxolitinib data are shown, including patients treated with ruxolitinib monotherapy (with or without placebo). SVR data were from 465 participants in three studies: COMFORT-1, SIMPLIFY-1, and TRANSFORM-1 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). TSS data were from 528 participants in these three studies. Week 24 data were used as a surrogate endpoint for assessing second-best response at week 18.

[0308] Step Two: From the pooled dataset, the mean SVR was 18% among JAKi-naïve MF patients who had a suboptimal response to ruxolitinib. Figure 15 ), and the average TSS decreased to 28.5% ( Figure 16 ).

[0309] This information was then combined with pre-randomization thresholds SVR25 and TSS30 to determine consistency with established clinical benefit history thresholds (e.g., SVR35 and TSS50) as measured from pre-ruxolitinib baseline in JAKi-naïve MF patients.

[0310] An additional 25% SVR for an average SVR of 18% would generate an effective response threshold of 39% from the pre-ruxolitinib baseline, exceeding the current SVR35 standard. Similarly, an additional 30% TSS reduction for an average TSS reduction of 28.5% would establish an effective response threshold of 50% from the pre-ruxolitinib baseline, consistent with the current TSS50 standard.

[0311] Step 3: Finally, the following two sets of results were compared for a concordance analysis: SVR25 and TSS30 (measured from baseline before randomization) versus SVR35 and TSS50 (measured from baseline before ruxolitinib). This analysis was performed to understand how well these results were concordant when assessing the effects of additional natedeline or additional placebo on suboptimal responders in the KRT-232-115 study.

[0312] Therefore, suboptimal responder patient data were compiled from publicly available phase 3 studies in JAKi-naïve MF (Verstovsek 2012; Mesa 2017; Pemmaraju 2023; Rampal 2023), along with results from KRT-232-109. Figure 17 , Figure 18 KRT-232-109 is a phase 2 study of adding natedeline in patients with a suboptimal response to ruxolitinib.

[0313] Figure 17 This study demonstrates spleen volume reduction in evaluable subjects with spleen volume assessment at baseline and week 24 following stable-dose ruxolitinib supplementation with atedrin. Baseline spleen volume MRI / CT scans were performed while subjects received stable-dose ruxolitinib for ≥8 weeks (e.g., without ruxolitinib washout). Figure 18 The study demonstrated a reduction in total symptom scores following the addition of naproxen to a stable dose of ruxotinib. Baseline TSS assessments were performed during the same period in which subjects received a stable dose of ruxotinib for ≥8 weeks (e.g., without ruxotinib washout). Figure 17 and Figure 18 During the 24-week evaluation period, no dose increases above the stable baseline for ruxolitinib occurred. The median duration of ruxolitinib treatment prior to the addition of atedrin was 21.6 months (range: 7 to 129). Six subjects discontinued treatment before week 24.

[0314] In these analyses, the contribution effect of natedrine to SVR and TSS from study KRT-232-109 was modeled onto pooled suboptimal responder data to establish the additional benefit of natedrine from the perspective of ruxolitinib pre-baseline. This model allowed for estimation of the proportion of suboptimal responders who would achieve SVR 25 or TSS 30 from their pre-randomization baseline.

[0315] Based on this model, it is projected that 55% of patients receiving additional natedeline will achieve an SVR35 from their pre-ruxolitinib baseline, and 50% will achieve an SVR25 from their pre-randomization baseline, compared to 8% and 0% for patients receiving additional placebo, respectively. Figure 19 , Figure 20 ). Figure 19 The expected SVR with ruxolitinib plus nutedrine is shown, with spleen volume reduction modeled by KRT-232-109 and published phase 3 myelofibrosis studies. Light gray bars depict the baseline SVR distribution, based on pooled extractable data from published phase 3 JAKi-naïve MF studies in patients with suboptimal spleen response to ruxolitinib monotherapy (± placebo); COMFORT-1, SIMPLIFY-1, and TRANSFORM-1 (Verstovsek 2012; Mesa 2017; Pemmaraju 2023). Blue bars (regardless of shade) show the expected additional benefit in patients treated with added nutedrine. The darkest blue bars depict SVR25 responders from pre-randomization baseline, which also cross the SVR35 threshold (e.g., multi-component SVR endpoint) from pre-ruxolitinib baseline. Figure 20The expected SVR with the addition of placebo to ruxolitinib is shown. The dark gray bars represent the expected additional benefit in patients treated with placebo. No patients (0% of patients) were modeled as reaching the multi-component SVR endpoints of SVR25 from pre-randomization baseline and SVR35 from pre-ruxolitinib baseline.

[0316] Similarly, it is projected that 45% of patients receiving additional natedeline will achieve a TSS50 from pre-ruxolitinib baseline, and 45% will achieve a TSS30 from pre-randomization baseline, compared to 9% and 2% respectively for patients receiving additional placebo. Figure 21 , Figure 22 ).

[0317] Figure 21 The expected TSS reduction with the addition of nutedrin to ruxolitinib is shown. Light gray bars depict the baseline distribution of TSS reduction, based on pooled extractable data from the published Phase 3 JAKi-naïve MF study of patients with suboptimal symptom responses to ruxolitinib monotherapy (± placebo). Green bars (regardless of shade) show the expected additional symptom improvement benefit in patients treated with the addition of nutedrin. The darkest green bars depict TSS30 responders from pre-randomization baseline, which also cross the TSS50 threshold (multi-component TSS endpoint) from pre-ruxolitinib baseline. Figure 22 The expected TSS reduction with the addition of placebo to ruxotinib is shown. Light gray bars depict the baseline distribution of TSS reduction, based on pooled extractable data from the published Phase 3 JAKi-naïve MF study of patients with suboptimal symptom responses to ruxotinib monotherapy (± placebo). Dark gray bars show the expected additional benefit for patients treated with placebo. Black bars depict TSS30 responders from pre-randomization baseline, which also cross the TSS50 threshold from pre-ruxotinib baseline (e.g., multi-component TSS endpoints).

[0318] A 93% concordance was observed between the expected SVR25 from the pre-randomization baseline and the expected SVR35 from the pre-ruxolinib baseline (e.g., 93% of SVR25 responders will also achieve SVR35 from the pre-ruxolinib baseline). Similarly, a 90% concordance was observed between the expected TSS30 from the pre-randomization baseline and the expected TSS50 from the pre-ruxolinib baseline (e.g., 90% of TSS30 responders will also achieve TSS50 from the pre-ruxolinib baseline).

[0319] References Al-Ali HK, Vannucchi AM. Managing patients with myelofibrosis and low platelet counts. Ann Hematol. Apr 2017;96(4):537-548. Aubrey BJ, Kelly GL, Janic A et al. . How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression Cell Death Differ. Jan 2018;25(1):104-113. Barosi G, Mesa RA, Thiele J et al. . Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. Feb 2008;22(2):437-8. Canon J, Osgood T, Olson SH et al. . The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther. Mar 2015;14(3):649-58. Cervantes F, Dupriez B, Pereira A et al. .New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. Mar 26 2009;113(13):2895-901. Clevenger T, Cheung J, Krantz F et al. . Adding Navtemadlin (nvtm) to Ruxolitinib (rux) Potentiates Apoptosis in Myeloblasts from Patients (pts) with Myelofibrosis (MF). presented at: EHA2023 Congress; 2023; Frankfurt, Germany. Erba HP, Becker PS, Shami PJ et al. . Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed / refractory acute myeloid leukemia. Blood Adv. Jul 9 2019;3(13):1939-1949. Fiedler W, Henke RP, Ergun S et al. . Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report. Cancer. Jan 15 2000;88(2):344-51. Food and Drug Administration. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. Greenfield G, McPherson S, Mills K et al. . The ruxolitinib effect:understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. Dec 17 2018;16(1):360. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare; 1976. Gwaltney C, Paty J, Kwitkowski VE et al. . Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res. Aug 2017;59:26-31. Harrison C, Kiladjian JJ, Al-Ali HK et al. . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. Mar 1 2012;366(9):787-98. Harrison CN, Vannucchi AM, Kiladjian JJ et al. . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. Aug 2016;30(8):1701-7. Harrison CN, Vannucchi AM, Platzbecker U et al. . Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. Feb 2018;5(2):e73-e81. Harutyunyan A, Klampfl T, Cazzola M et al. . p53 lesions in leukemic transformation. N Engl J Med. Feb 3 2011;364(5):488-90. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. May 2009;82(5):329-38. Jakafi Prescribing Information. Jakafi® (ruxolitinib) prescribing information. Available on the Internet at jakafi.com / pdf / prescribing-information.pdf Kvasnicka HM, Thiele J, Bueso-Ramos CE et al. . Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. Mar 15 2018;11(1):42. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. Dec 2017;85:58-63. Mascarenhas J, Hoffman R, Talpaz M et al. . Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients with Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. May 1 2018;4(5):652-659. Mascarenhas J, Jain T, Otoukesh S et al. . An Open-Label, Global, Phase 1B / 2 Study Adding Navtemadlin (NVTM) to Ruxolitinib (RUX) in Patients (PTS) with Primary or Secondary Myelofibrosis (MF) Who Have a Suboptimal Response to RUX. presented at: EHA 2023 Congress; 2023; Frankfurt, Germany. Mesa RA, Gotlib J, Gupta V et al. . Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. Apr 1 2013;31(10):1285-92. Mesa RA, Kiladjian J-J, Catalano JV et al. .SIMPLIFY-1: A Phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor–naïve patients with myelofibrosis. Journal of Clinical Oncology. 2017;35(34):3844-3850. Nakatake M, Monte-Mor B, Debili N et al. . JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. Mar 8 2012;31(10):1323-33. National Institute of Mental Health (NIMH). Patient global impression of change (PGIC). 2017. Available on the Internet at eprovide.mapi-trust.org / instruments / patient-global-impression-of-change. Newberry KJ, Patel K, Masarova L et al. . Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. Aug 31 2017;130(9):1125-1131. Orvain C, Luque Paz D, Dobo I et al. .Circulating CD34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol. Oct 2016;95(11):1819-23. Palandri F, Breccia M, Bonifacio M et al. . Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. Mar 15 2020;126(6):1243-1252. Pardanani A, Harrison C, Cortes JE et al. . Safety and Efficacy of Fedratinib in Patients with Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. Aug 2015;1(5):643-51. Pemmaraju N, Mead AJ, Somervaille TC et al. . Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Blood. 2023 Nov 28;142:620. Pikman Y, Lee BH, Mercher T et al. .MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. Jul 2006;3(7):e270. Rampal RK, Grosicki S, Chraniuk D et al. . Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study. Blood . 2023;142(1):628. Raza S, Viswanatha D, Frederick L et al. . TP53 mutations and polymorphisms in primary myelofibrosis. Am J Hematol. Feb 2012;87(2):204-6. Sun D, Li Z, Rew Y et al. . Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem. Feb 27 2014;57(4):1454-72. Tefferi A, Cervantes F, Mesa R et al. .Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. Aug 22 2013;122(8):1395-8. Tefferi A, Thiele J, Orazi A et al. . Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. Aug 15 2007;110(4):1092-7. Thiele J, Kvasnicka HM, Facchetti F et al. . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. Aug 2005;90(8):1128-32. Vachhani P, Lange A, Delgado RG et al. . Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed / Refractory Myelofibrosis (MF). Blood. 2021;138:3581-3584. Vachhani P, Perkins A, Mascarenhas J et al. . Disease-modifying activity of navtemadlin correlated with survival outcomes in Janus kinase inhibitor (JAKi) relapsed or refractory myelofibrosis patients. presented at: European Hematology Association; 2023; Frankfurt. Vannucchi AM, Kantarjian HM, Kiladjian JJ et al. . A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. Sep 2015;100(9):1139-45. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta. May 2009;1787(5):414-20. Verstovsek S, Mesa RA, Gotlib J et al. . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. Feb 22 2017;10(1):55. Verstovsek S, Mesa RA, Gotlib J et al. .A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. Mar 12012;366(9):799-807. Vousden KH, Lane Dp. p53 in health and disease. Nat Rev Mol CellBiol. Apr 2007;8(4):275-83.

[0320] in conclusion All references cited in this article are incorporated herein in their entirety by reference and for all purposes, to the same extent that each individual publication, patent, or patent application is explicitly and individually indicated to be incorporated herein in its entirety by reference for all purposes.

[0321] This invention can be implemented as a computer program product comprising a computer program mechanism embedded in a non-transitory computer-readable storage medium. For example, the computer program product may include... Figure 1A Program modules are shown in any combination of -C or 2A-C. These program modules may be stored on CD-ROM, DVD, disk storage products, USB keys, or any other non-transitory computer-readable data or program storage products.

[0322] Many modifications and variations can be made to this invention without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are provided by way of example only. These embodiments were chosen and described in order to best explain the principles of the invention and its practical application, thereby enabling others skilled in the art to best utilize the invention and its various embodiments with various modifications to suit the particular purpose in mind. This invention is limited only by the terms of the appended claims and the full scope of their equivalents.

Claims

1. A method for determining whether treatment with a combination of a first composition and a second composition improves one or more endpoints associated with myeloproliferative neoplasms relative to monotherapy with the first composition, the method comprising: Obtain clinical data involving multiple subjects with myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition and (ii) a corresponding first set of responses after a first treatment period with the first composition; Identify a subset of subjects from the plurality of subjects, each of whom satisfies the suboptimal response threshold; The subset of subjects was randomly divided into a first arm and a second arm, wherein for the second treatment period, subjects in the first arm received a combination of the first composition and the second composition, while subjects in the second arm received a combination of the first composition and a placebo. For each corresponding subject in the subset of subjects, a corresponding second response set is obtained upon completion of the second treatment period; and Each corresponding subject in the subset of subjects is evaluated by comparing the corresponding second response set with the following: (a) The corresponding first set of baseline measurements and / or (b) Optional second set of baseline measurements obtained from the respective subjects after the subset of subjects was divided into the first arm and the second arm and before treatment with the combination of the first composition and the second composition or the combination of the first composition and the placebo. This determines whether the combination of the first treatment and the second treatment in the first arm improves the one or more endpoints associated with myeloproliferative neoplasms relative to the single therapy using the first composition.

2. The method of claim 1, wherein each corresponding subject in the subset of subjects is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding first set of baseline measurements.

3. The method of claim 1, further comprising obtaining corresponding second set of baseline measurements for each subject after the subset of subjects has been divided into the first arm and the second arm and before treatment with the combination of the first composition and the second composition or the combination of the first composition and the placebo. Furthermore, each corresponding subject in the subject subset is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding second set of baseline measurements.

4. The method of claim 1, wherein one of the one or more endpoints is a comparison: The first arm displays the proportion of subjects whose spleen size reduction, as measured by magnetic resonance imaging or computed tomography, is greater than a spleen size reduction threshold between a set time during the induction period and the second treatment period. The second arm displays the proportion of subjects whose spleen size reduction is greater than a spleen size reduction threshold, as measured by magnetic resonance imaging or computed tomography, between a set time in the induction period and the second treatment period.

5. The method according to claim 4, wherein The first treatment period is between 12 and 36 weeks, and The timing of the second treatment period is between 12 and 36 weeks after the start of the second treatment period.

6. The method of claim 4, wherein The first treatment period is between 12 and 36 weeks, and The set time for the second treatment period is 24 weeks after the start of the second treatment period.

7. The method of any one of claims 4-6, wherein the spleen size reduction threshold is a percentage between 25% and 50% of the first baseline spleen size measurement relative to the corresponding first set of baseline spleen size measurements.

8. The method of any one of claims 4-6, wherein the spleen size reduction threshold is at least 35% of a first baseline spleen size measurement relative to a corresponding first set of baseline measurements.

9. The method according to any one of claims 1-8, wherein the endpoint of the one or more endpoints is a comparison: The first arm displays the proportion of subjects whose quality of life assessment scores improved by more than a threshold amount between the set time intervals of the induction and second treatment periods, and... The second arm displays the proportion of subjects whose quality of life assessment scores improved by more than the improvement threshold between a set time during the induction period and the second treatment period.

10. The method of claim 9, wherein The first treatment period is between 12 and 36 weeks, and The timing of the second treatment period is between 12 and 36 weeks after the start of the second treatment period.

11. The method of claim 9, wherein The first treatment period is between 12 and 36 weeks, and The set time for the second treatment period is 24 weeks after the start of the second treatment period.

12. The method according to any one of claims 9-11, wherein for subjects in the subset of subjects: The corresponding first set of baseline measurements includes the first score derived from the quality of life assessment scale. The corresponding second response set includes a second score derived from a quality of life assessment scale, and The improvement in the quality of life assessment score between the set time in the induction period and the second treatment period is the difference between the first score and the second score.

13. The method of claim 12, wherein the quality of life assessment form is a myelofibrosis symptom assessment form or a myeloproliferative neoplasm symptom assessment form v2.

0.

14. The method of claim 12, wherein the quality of life assessment form is the General Quality of Life Questionnaire (EQ-5D), eHEALS, EORTC QLG Core Questionnaire (EORTC QLQ-C30), Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and / or Patient Activation Scale (PAM-13).

15. The method of any one of claims 7-13, wherein the quality of life assessment form is the myeloproliferative neoplasm symptom assessment form v2.0, and the improvement threshold is a reduction of at least 60 percent in the quality of life assessment score.

16. The method of any one of claims 7-13, wherein the quality of life assessment form is the myeloproliferative neoplasm symptom assessment form v2.0, and the improvement threshold is a reduction of at least fifty percent in the quality of life assessment score.

17. The method according to any one of claims 1-16, wherein One of the one or more endpoints is a comparison between the calculation of the first total survival value and the calculation of the second total survival value. The first overall survival value is calculated as a central tendency measure of the difference between the following two factors across subjects in the first arm: (i) the time of enrollment during the induction period, and (ii) the time of death, for any cause, and The second overall survival value is calculated as a central tendency measure of the difference between the following two factors across subjects in the second arm: (i) the time of enrollment during the induction period, and (ii) The time of death, for any reason.

18. The method according to any one of claims 1-17, wherein One of the one or more endpoints is a comparison between the calculation of a first progression-free survival value and the calculation of a second progression-free survival value. The first progression-free survival value is calculated as a central tendency measure of the difference between the following two values ​​across subjects in the first arm: (i) the time of enrollment during the induction period, and (ii) (a) The spleen size exceeds the threshold percentage of spleen volume at the start of the induction period, (b) leukemia transformation, or (c) the time of the first occurrence of death from any cause, and The second progression-free survival value is calculated as a central tendency measure of the difference between the following two factors across subjects in the second arm: (i) the time of enrollment during the induction period, and (ii) (a) The time when the spleen size increases beyond the threshold amount at the start of the induction period, (b) the time of leukemia transformation, or (c) the time of the first occurrence of death from any cause.

19. The method of claim 18, wherein the threshold percentage spleen volume is 15% to 35% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements.

20. The method of claim 18, wherein the threshold percentage spleen volume is 25% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements.

21. The method of claim 18, wherein the leukemia transformation comprises: (i) A bone marrow blast count ≥20% higher than the bone marrow blast count at enrollment during the induction period, and a count exceeding 1x10 for at least 2 weeks. 9 The absolute primitive cell count per L is correlated with, and / or (ii) The peripheral blood blast cell content is ≥20% higher than the peripheral blood blast cell content at the time of enrollment during the introduction period, and exceeds 1x10 for at least 2 weeks. 9 This is correlated with the absolute primitive cell count per L.

22. The method of any one of claims 1-21, wherein the endpoint of the one or more endpoints is a comparison of a first average time quantity with a second average time quantity, wherein The first average time amount is between the following two: (i) the time at which the spleen size reduction of at least a threshold percentage of spleen volume is first observed after the induction period, and (ii) The time at which disease progression or death was observed in subjects spanning the first arm, and The second average time amount is between the following two: (i) the time at which the spleen size reduction of at least the threshold percentage is first observed after the induction period, and (ii) The time when disease progression or death was observed in the subject across the second arm.

23. The method of claim 22, wherein the threshold percentage spleen volume is between 35% and 45% of the first baseline spleen volume measurement in the corresponding first set of baseline spleen volume measurements.

24. The method of claim 22, wherein the threshold percentage spleen volume is 35% of the first baseline spleen volume measurement relative to the corresponding first set of baseline spleen volume measurements.

25. The method of any one of claims 1-24, wherein the endpoint of the one or more endpoints is a comparison: The first arm displays the proportion of subjects whose spleen size reduction, as measured by palpation, is greater than a spleen size reduction threshold between a set time during the induction and second treatment periods. The second arm displays the proportion of subjects whose spleen size reduction, as measured by palpation, is greater than the spleen size reduction threshold between a set time during the induction period and the second treatment period.

26. The method according to any one of claims 1-25, wherein The corresponding first set of baseline measurements includes the first measurement value of the corresponding subject's organ, while The corresponding second response set includes the second measurement values ​​of the corresponding subject's organs.

27. The method of claim 26, wherein the organ is the spleen of the respective subject.

28. The method of claim 26, wherein The first measurement value of the corresponding subject organ is the first measurement value of the spleen size of the corresponding subject, and The second measurement of the corresponding subject organ is the second measurement of the size of the corresponding subject's spleen.

29. The method of any one of claims 1-28, wherein the plurality of subjects comprises 200 subjects.

30. The method of any one of claims 1-28, wherein the plurality of subjects comprises 500 subjects.

31. The method of any one of claims 1-30, wherein less than 80 percent of the plurality of subjects meet the suboptimal response threshold.

32. The method of any one of claims 1-30, wherein less than 40 percent of the plurality of subjects meet the suboptimal response threshold.

33. The method according to any one of claims 1-32, wherein the myeloproliferative tumor is myelofibrosis.

34. The method of any one of claims 1-33, wherein the plurality of subjects are untreated with JAK inhibitors.

35. The method of any one of claims 1-34, wherein each of the plurality of subjects has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 in the corresponding first set of baseline measurements.

36. The method of any one of claims 1-35, wherein each of the plurality of subjects has a value greater than or equal to 450 cm⁻¹ in the corresponding first set of baseline measurements, as determined by magnetic resonance imaging or computed tomography. 3 The spleen measurement values.

37. The method of any one of claims 1-36, wherein each of the plurality of subjects has 100x10 in the corresponding first set of baseline measurements. 9 A platelet count of 1 / L or higher.

38. The method according to any one of claims 1-37, wherein the first treatment period is greater than 5 weeks and less than 40 weeks.

39. The method according to any one of claims 1-37, wherein the first treatment period is equal to or greater than 12 weeks and less than 36 weeks.

40. The method of claim 38 or 39, wherein the first treatment period comprises daily administration of the first composition for at least 5 weeks without treatment interruption or dose adjustment.

41. The method of claim 38 or 39, wherein the first treatment period comprises daily administration of the first composition for at least 8 weeks without treatment interruption or dose adjustment.

42. The method according to any one of claims 1-41, wherein the second treatment period is 5 weeks to 100 weeks.

43. The method according to any one of claims 1-41, wherein the second treatment period is 12 weeks to 200 weeks.

44. The method according to any one of claims 1-43, wherein the active ingredient of the first therapeutic composition is ruxolitinib.

45. The method of claim 44, wherein during the first treatment period and the second treatment period, the plurality of subjects are administered a total daily dose of ≥ 3 mg of ruxotinib.

46. ​​The method of claim 44, wherein during the first treatment period and the second treatment period, the plurality of subjects are administered a total daily dose of ≥ 5 mg of ruxotinib.

47. The method of claim 44, wherein during the first treatment period and the second treatment period, the plurality of subjects are administered a total daily dose of ≥ 8 mg of ruxolitinib.

48. The method of claim 44, wherein during the first treatment period and the second treatment period, ruxotinib is administered to the plurality of subjects at a total daily dose between 2 mg and 10 mg.

49. The method of any one of claims 44-48, wherein the ruxolitinib is administered twice a day.

50. The method of any one of claims 44-48, wherein the ruxolitinib is administered once daily.

51. The method according to any one of claims 1-50, wherein the active ingredient of the second therapeutic composition is natedrine.

52. The method of claim 51, wherein during the second treatment period, each subject in the first arm is administered a total daily dose of ≥100 mg of natedrine.

53. The method of claim 51, wherein during the second treatment period, each subject in the first arm is administered a total daily dose of ≥ 200 mg of natedrine.

54. The method of claim 51, wherein during the second treatment period, each subject in the first arm is administered a total daily dose of natadeline between 50 mg and 300 mg.

55. The method of claim 51, wherein during the second treatment period, each subject in the first arm is administered a total daily dose of 240 mg of natedrine.

56. The method of any one of claims 51-55, wherein during the second treatment period, natadeline is administered twice daily to each subject in the first arm.

57. The method of any one of claims 51-55, wherein during the second treatment period, natadeline is administered once daily to each subject in the first arm.

58. The method according to any one of claims 1-57, wherein the corresponding first response set of the relevant subject satisfies the suboptimal response threshold when the following condition exists: (i) Between the baseline measurement and the period following the first treatment, the spleen size decreased by more than 0% and 50%, and / or (ii) Between the baseline measurement and the end of the first treatment period, the total symptom score reduction is between 0% and 70%.

59. The method according to any one of claims 1-57, wherein the corresponding first response set of the relevant subject satisfies the suboptimal response threshold when the following condition exists: (i) Between the baseline measurement and the period following the first treatment, the spleen size decreased by more than 0% and 40%, and / or (ii) Between the baseline measurement and the end of the first treatment period, the total symptom score reduction is between 0% and 60%.

60. The method of any one of claims 1-57, wherein the corresponding first response set of the relevant subject satisfies the suboptimal response threshold when the following condition exists: (i) Between the baseline measurement and the period following the first treatment, the spleen size decreased by more than 0% and 35%, and / or (ii) Between the baseline measurement and the end of the first treatment period, the total symptom score reduction is between 0% and 50%.

61. The method of any one of claims 1-60, wherein dividing the subset of subjects into the first arm and the second arm on a randomization basis is based on a stratified, permutation block randomization scheme that balances the representativeness of each block in the first and second arms for a plurality of blocks, wherein The first block of the plurality of blocks is SVR >0% but <20%, while The second block of the plurality of blocks is an SVR ≥ 20% but < 35%.

62. The method of claim 61, wherein The third block of the multiple blocks is where TSS decreases by >0% but <30%, while The fourth block among the multiple blocks is defined as a TSS reduction of ≥30% but <50%.

63. A computing system, comprising: A computer memory configured to store clinical data relating to multiple subjects suffering from myeloproliferative neoplasms, wherein for each of the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with a first treatment of the first composition or a second treatment of the second composition for the myeloproliferative neoplasm and (ii) a corresponding first set of responses after a first treatment period with the first composition; One or more processors that communicate with the computer memory and are configured to execute program instructions to perform the following operations: Identify a subset of subjects from the plurality of subjects, each of whom satisfies the suboptimal response threshold; The subject subset was randomly divided into a first arm and a second arm, wherein for the second treatment period, subjects in the first arm received a combination of the first composition and the second composition, while subjects in the second arm received a combination of the first composition and a placebo. For each corresponding subject in the subset of subjects, a corresponding second response set is obtained upon completion of the second treatment period, and Each corresponding subject in the subject subset is evaluated by comparing the corresponding second response set with the following: (a) The corresponding first set of baseline measurements and / or (b) Optional second set of baseline measurements obtained from the respective subjects after the subject subset was divided into the first arm and the second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo. This determines whether the combination of the first treatment and the second treatment in the first arm improves the one or more endpoints associated with myeloproliferative neoplasms relative to a single therapy using the first composition.

64. The computational system of claim 63, wherein each corresponding subject in the subset of subjects is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding first set of baseline measurements.

65. The computing system of claim 63, further comprising: After the subset of subjects was divided into the first arm and the second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, corresponding second set of baseline measurements were obtained for the respective subjects, wherein: Each corresponding subject in the subject subset is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding second set of baseline measurements.

66. A non-transitory computer-readable storage medium, wherein the non-transitory computer-readable storage medium stores instructions, which, when executed by a computer system, cause the computer system to perform a method for determining whether combined treatment with a first composition and a second composition improves one or more endpoints related to myeloproliferative neoplasms relative to monotherapy with the first composition, the method comprising: Obtain clinical data involving multiple subjects with myeloproliferative neoplasms, wherein for each corresponding subject among the multiple subjects, the clinical data includes and is associated with: (i) a corresponding first set of baseline measurements prior to treatment with the first composition and (ii) a corresponding first set of responses after a first treatment period with the first composition; Identify a subset of subjects from the plurality of subjects, each of whom satisfies the suboptimal response threshold; The subset of subjects was randomly divided into a first arm and a second arm, wherein for the second treatment period, subjects in the first arm received a combination of the first composition and the second composition, while subjects in the second arm received a combination of the first composition and a placebo. For each corresponding subject in the subset of subjects, a corresponding second response set is obtained upon completion of the second treatment period, and Each corresponding subject in the subset of subjects is evaluated by comparing the corresponding second response set with the following: (a) The corresponding first set of baseline measurements and / or (b) Optional second set of baseline measurements obtained from the respective subjects after the subset of subjects was divided into the first arm and the second arm and before treatment with the combination of the first composition and the second composition or the combination of the first composition and the placebo. This determines whether the combination of the first treatment and the second treatment in the first arm improves the one or more endpoints associated with myeloproliferative neoplasms relative to a single therapy using the first composition.

67. The non-transitory computer-readable storage medium of claim 66, wherein each corresponding subject in the subset of subjects is evaluated by comparing a corresponding second response set of the corresponding subject with a corresponding first set of baseline measurements.

68. The non-transitory computer-readable storage medium of claim 66, further comprising: After the subset of subjects was divided into the first arm and the second arm and before treatment with a combination of the first composition and the second composition or a combination of the first composition and placebo, corresponding second set of baseline measurements were obtained for the respective subjects, wherein: Each corresponding subject in the subject subset is evaluated by comparing the corresponding second response set of the corresponding subject with the corresponding second set of baseline measurements.

69. The method of any one of claims 4-6, wherein the spleen volume reduction threshold is between 25% and 50% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements.

70. The method of any one of claims 4-6, wherein the spleen volume reduction threshold is at least 35% of a second baseline spleen volume measurement relative to a corresponding second set of baseline spleen volume measurements.

71. The method of claim 18, wherein the threshold percentage spleen volume is 15% to 35% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements.

72. The method of claim 18, wherein the threshold percentage spleen volume is 25% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements.

73. The method of claim 22, wherein the threshold percentage spleen volume is between 35% and 45% of the second baseline spleen volume measurement in the corresponding second set of baseline spleen volume measurements.

74. The method of claim 22, wherein the threshold percentage spleen volume is 35% of the second baseline spleen volume measurement relative to the corresponding second set of baseline spleen volume measurements.

75. The method of any one of claims 1-62, wherein the endpoint of the one or more endpoints is a secondary efficacy endpoint selected from SVR25, TSS30, SVR35, and TSS50, determined by comparing the corresponding second response set with corresponding first set of baseline measurements prior to treatment with the first composition and corresponding second set of baseline measurements prior to treatment with a combination of the first composition and the second composition or a combination of the first composition and the placebo.

76. The method of any one of claims 1-62, further comprising, after identifying the subsets of subjects that each of the plurality of subjects satisfies a suboptimal response threshold, and before dividing the subsets of subjects into the first arm and the second arm: For the first block among multiple blocks, the subset of subjects is restricted such that the proportion of subjects represented by the first block in the subset of subjects is not greater than the inclusion threshold.

77. The method of claim 76, wherein the first block is a spleen size reduction of 30% to 35%, and the inclusion threshold is 15%.

78. The method of any one of claims 1-62, wherein the endpoint is SVR25 and SVR35, wherein SVR25 is determined by comparing the corresponding second response set with a corresponding second set of baseline spleen volume measurements of the corresponding subject obtained prior to treatment with the combination of the first composition and the second composition; wherein SVR35 is determined by comparing the corresponding second response set with a corresponding first set of baseline spleen volume measurements of the corresponding subject obtained prior to treatment with the first composition.

79. The method of any one of claims 1-62, wherein the endpoint is TSS30 and TSS50; wherein TSS30 is determined by comparing the corresponding second response set with corresponding second set of baseline TSS measurements of the corresponding subject obtained prior to treatment with the combination of the first composition and the second composition; wherein TSS50 is determined by comparing the corresponding second response set with corresponding first set of baseline TSS measurements of the corresponding subject obtained prior to treatment with the first composition.

80. The method of any one of claims 1-62, wherein the endpoint is SVR25, SVR35, TSS30, and TSS50; wherein SVR25 and TSS30 are determined by comparing the corresponding second response set with corresponding second set of baseline measurements of the corresponding subjects obtained prior to treatment with the combination of the first composition and the second composition; wherein SVR35 and TSS50 are determined by comparing the corresponding second response set with corresponding first set of baseline measurements of the corresponding subjects obtained prior to treatment with the first composition.